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Abstract

COMBINED ANTIPROLIFERATIVE EFFECTS OF THE AMINOALKYLINDOLE WIN55,212-2
AND RADIATION IN BREAST CANCER CELLS

By Sean Emery PhD

A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University.

Virginia Commonwealth University, 2014
Major Director: David A. Gewirtz, Professor of Pharmacology and Toxicology

The potential antitumor activity of mixed CB1/CB2 cannabinoid receptor agonists, such as the
aminoalkylindole WIN55,212-2 (WIN2), has been extensively studied, but little information is
available as to their potential interaction with conventional cancer therapies, such as ionizing
radiation (IR). In the present work, we investigated the effects of WIN2 on the antiproliferative
effects of radiation in human (MCF-7 and MDA-MB-231) and murine (4T1) breast cancer cells,
as well as an immortalized human breast epithelial cell line (MCF-10A). WIN2 or radiation alone
inhibited breast tumor growth, while the combination of WIN2 and radiation was more effective
than either agent alone in breast cancer cells. WIN2 showed lower potency in MCF-10A cells
than MCF-7 cells, but was still able to augment the effects of radiation at higher doses. The
stereoisomer of WIN2, WIN55,212-3 (WIN3) failed to inhibit growth or potentiate the growthinhibitory effects of radiation, indicating stereospecificity in all cell lines tested. The combination
of WIN2 and IR was examined in vivo but the results were inconclusive. Interestingly, while
other aminoalkylindoles, pravadoline and JWH-015, enhanced the antiproliferative effects of
radiation, this was not the case for other synthetic cannabinoids (i.e., nabilone, CP55,940 and
methanandamide) or phytocannabinoids (i.e., ∆9-tetrahydrocannabinol and cannabidiol). The
3

antiproliferative actions of WIN2 were not ameliorated by CB1, CB2, TRPV1, or PPAR receptor
antagonists, suggesting the possibility of a novel site of action. Studies utilizing sphingosine-1phosphate (S1P) agonists and estradiol suggest that WIN2 interferes with S1P signaling in cell
proliferation, but agonist stimulated [³⁵S]GTPγS binding assays show that this antagonism is not
occurring at the level of S1P receptors. In addition, WIN2 did not alter radiation-induced DNA
damage or the rate of DNA repair based on γH2AX staining. Treatment with WIN2 and radiation
promoted both autophagy and senescence, but not apoptosis or necrosis. Time course studies
combined with senescence and cell death data suggest that radiation-induced senescence,
while WIN2 induced classical growth arrest and the WIN2/IR combination produced parallel
mechanisms of both senescent growth arrest and classical growth arrest. Taken together, these
findings raise the possibility that aminoalkylindole compounds targeting a novel site of action
represents a potential strategy to augment the effectiveness of radiation treatment in breast
cancer.
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General background

Breast cancer and breast cancer therapy

Breast cancer is a mammary tissue derived neoplastic disease typically beginning as a
solid tumor and progressing to a malignant and metastatic disease. The surveillance,
epidemiology and end result (SEER) program of the National Cancer Institute collects valuable
information about cancer prevalence in the United States. According to the SEER report, an
estimated 232,340 new cases of breast cancer were diagnosed in 2013, which comprised 14.1
percent of all cancer diagnoses. Breast cancer almost exclusively presents in women but 0.51% of all cases are diagnosed in men (Ruddy et al. 2013). The high yearly diagnosis rate
translates to an estimated 2.82 million women currently living with breast cancer. With such a
high rate of diagnosis, breast cancer is the most common cancer among women and the
second most common cancer overall behind prostate cancer. About 12.3 percent of all women
will be diagnosed with a form of breast cancer at some point in their lifetime, but fortunately
breast cancer has a relatively high 5 year survival rate at 89.2 percent of cases. Despite this,
the high occurrence rate for breast cancer diseases will lead to an estimated 39,620 deaths in
2013, making breast cancer the third leading cause of cancer related deaths in the United
States. This high mortality rate indicates that more effective therapies need to be developed.
Current treatment paradigms consist of three primary therapies, specifically including surgery,
chemotherapy and radiation (Kaviani et al. 2013; Joerger et al. 2013; Yang et al. 2013; den
Hollander et al. 2013), and depending on the type of breast cancer targeted therapies such as
hormone based therapy can also be used (den Hollander et al. 2013).
After diagnosis of a breast tumor, a surgical consultation can lead to one of two primary
options for treatment including breast conserving therapy or mastectomy. The choice of which of
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these options is to be used is dependent on the state of the disease based on biopsy and/or the
extent of the malignant spread. Breast conserving therapy primarily aims to eliminate the bulk of
primary tumors and remaining tumor cells are treated with radiation and chemotherapy. The
goal of a mastectomy is to eliminate the primary tumor and other remaining tumor cells by
complete removal to the breast tissue, which eliminates the tumor bed. Chemotherapy and
radiation are also used in conjunction with mastectomies to decrease relapse rates (Kaviani et
al. 2013).
Chemotherapeutics function in a variety of ways depending on the drug class. Use of
these therapeutic agents has evolved over the years as clinical knowledge of breast cancer has
expanded.

Breast

cancer

has

primarily

been

treated

with

five

drugs

including,

cyclophosphamide, methotrexate, 5-fluorouracil, doxorubicin and paclitaxel, but the current front
line chemotherapeutic treatments are doxorubicin and paclitaxel, which are also the most
recently developed of the five. Doxorubicin (Adriamycin) is a topoisomerase 2 poison capable of
causing DNA damage during DNA replication by preventing DNA religation. Paclitaxel is a
microtubule poison that inhibits cell division as the cancer cell goes through mitosis. Utilization
of doxorubicin and paclitaxel, as well as other chemotherapeutics, is at the discretion of what
the oncologist feels will be the most effective treatment (Joerger et al. 2013).
A powerful addition to the traditional adjuvant chemotherapies has been neoadjuvant
therapies designed to inhibit specific signaling pathways in cancer. These treatments are also
referred to as targeted therapies. The most successful targeted therapeis in breast cancer
include estrogen receptor antagonists, aromatase inhibitors and HER2/neu receptor
antagonists. Estrogen receptor positive breast cancers depend on estrogen signaling to
stimulate growth and promote tumor progression. Inhibition of the pro-cancer effects of estrogen
receptor signaling is executed with estrogen receptor antagonists such as tamoxifen. Another
mechanism by which breast cancers use to enhance estrogen signaling is via overexpression of
15

aromatase to increase local conversion of steroid precursors to estrogen. Aromatase inhibitors
were developed to inhibit this process and decrease estrogen based signaling. Finally, a
particularly aggressive form of breast cancer over-expresses the epidermal growth factor
receptor HER2/neu, which can fuel tumor growth and survival. Recently developed antibody
based antagonists of this receptor such as trastuzamab have proven to another useful tool for
improving patient survival (den Hollander et al. 2013).
In contrast to the relatively recent development of targeted therapies, radiation therapy
has been a component of cancer therapy almost since the discovery in the early 1900s that
ionizing radiation reduced tumor volume. Typical radiation therapy consists of 20-30 treatments
of 2 gray (Gy) doses of ionizing radiation. Depending on the tumor, radiation treatments can be
given pre-mastectomy, post-mastectomy or as a part of breast sparing surgery (Yang et al.
2013). The goal of radiation therapy is to inhibit tumor growth and recurrence, and these actions
are linked to the DNA damaging effects of ionizing radiation. The primary mechanism for
radiation-induced DNA damage is believed to be radiolysis of water leading to the formation of
reactive oxygen species (ROS) (Narayanan et al. 1997). ROS formation of DNA damage is
expressed as single and double strand breaks in DNA (Driessens et al. 2009).

Current cannabinoid use in cancer therapy

Cannabinoids are a class of compounds originally classified by their psychoactive
effects, which are most often associated with marijuana use and abuse (Howlett et al. 2002;
Pertwee et al. 2010). The cannabinoids Δ9-tetrahydrocannabinol (THC; Marinol) and nabilone
(Cesamet) are approved by the Food and Drug Administration (FDA) for the treatment of emesis
and nausea associated with cancer chemotherapy, and in the United States these remain the
only federally approved cannabinoid treatments (Russo 2008). THC is the primary psychoactive
16

component of marijuana and nabilone is a synthetic analog of THC (Howlett et al. 2002;
Pertwee et al. 2010).
The current FDA approval of Marinol and Cesamet indicates these drugs showed
acceptable minimally detected negative effects on patient treatment during clinical trials, but the
epidemiological literature has multiple reports that point to mixed views on cannabinoid action in
the development of cancer. Three reports have linked Marijuana use to increased incidents of
testicular cancer (Daling et al. 2009; Trabert et al. 2011; Lacson et al. 2012), but three other
studies reported that marijuana use is not significantly correlated to lung cancer development
(Sidney et al. 1997; Hashibe et al. 2006; Mehra et al. 2006). These studies suggest that
marijuana smoke contains carcinogens similar to tobacco smoke that are not related to the
cannabinoid compounds, and that these carcinogens could be a confounding factor of the
comparisons. Resultantly, cannabinoid treatments effects on tumor development remain
unresolved.
Even though the epidemiological literature has not reached a consensus on the effects
of cannabinoids in tumor development, preclinical cancer treatment literature is in fairly strong
agreement that cannabinoids have potential uses as anti-cancer agents. These observations
begin with a 1975 report by Munson et al. where THC, Δ8-tetrahydrocannabinol and cannabinol
inhibited growth of Lewis lung carcinoma cells in BDF mice leading to a significant increase in
survival rates of the animals. Analysis of in vitro studies indicated THC decreases cell
proliferation based on [3H]-thymidine incorporation. Since the Munson et al. (1975) study,
research has elucidated numerous mechanisms by which cannabinoids act in the body, both in
non-cancerous and cancerous tissues.
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The endocannabinoid system and cannabinoid sensitive receptors in preclinical cancer
research

Cannabinoid receptor 1
Cannabinoid receptor 1 (CB1) is a G protein coupled receptor (GPCR) first identified
after cloning from a rat brain cDNA library. Transfection of the putative CB1 receptor into CHOK1 cells allowed cannabinoid agonists to inhibit forskolin stimulated cAMP production, a
characteristic action of cannabinoids (Matsuda et al. 1990). CB1 is found abundantly in the
central nervous system, where its primary function is to suppress neurotransmitter release
halting stimulation of postsynaptic neurons (Hoffman et al. 2000; Howlett et al. 2002; Pertwee et
al. 2005). Additional research has implicated CB1 in the antiproliferative actions of anandamide
(AEA) in MCF-7 cells when the CB1 selective antagonist SR141716 (SR1) completely blocked
AEA induced growth inhibition (Melck et al. 2000). Similar findings were reported in U87-MG
glioma cells, where SR1 blocked THC mediated induction of autophagy and apoptosis (Salazar
et al. 2009). The Melck et al. and Slazar et al. studies exemplify that CB1 action extends beyond
mediating the psychoactive activities of cannabinoid in the CNS, and possess additional abilities
to inhibit tumor growth.

Cannabinoid receptor 2
In addition to CB1, a second cannabinoid receptor has been identified and also shown to
mediate anti-tumor effects of cannabinoids. Screening in HL60 leukemia cells identified several
new receptors, one of which showed 48 percent sequence homology to CB1 receptors. Cloning
of the HL60 derived receptor into COS cells allowed for binding of radiolabelled cannabinoids to
identify its cannabinoid activity (Munro et al. 1993). The receptor was then identified as
cannabinoid receptor 2 (CB2), which like CB1 receptors, is also a GPCR. CB2 is found primarily
18

in immune cells circulating in the body. Primary function of CB2 is believed to be modulation of
immune function by altering immune cell migration and cytokine release (Kaminski et al. 1992;
Howlett et al. 2002; Pertwee et al. 2002). CB2 has a documented role in cancer to mediate
cannabinoid based antiproliferative effects in multiple studies. Caffarel et al. (2006) showed that
the CB2 antagonist, SR144528 (SR2), but not SR1 significantly blocked the antiproliferative
effects of THC in EVSA-T breast cancer cells. CB2 involvement in cancer was later supported
when the CB2 selective cannabinoid agonist JWH-133 was shown to decrease the volume of
genetically derived Erb-B2 positive mammary tumors in mice (Caffarel et al. 2010). CB2
involvement also extends to prostate cancer where SR2, but not SR1, blocked the induction of
apoptosis in PC-3 cells induced by both methanandamide and the CB2 selective agonist JWH015 (Olea-Herrero et al. 2009).

Cannabinoid receptor-independent effects
In

contrast

to

the

aforementioned

studies,

cannabinoid

receptor-independent

antiproliferative effects have also been reported in cancer cells. Cannabidiol (CBD), a marijuana
derived cannabinoid, inhibited growth of U87 glioma cells in a manner that was not
antagonizable by SR1 or SR2 (Vaccani et al. 2005). Similarly, the cannabinoid selective
antagonists AM251 (CB1) and AM630 (CB2) did not block HU-210 and AEA growth inhibition in
Caco-2 colorectal cells (Gustafsson et al. 2009). Also WIN55, 212-2 (WIN2) growth inhibition
was not blocked by SR1 or SR2 in Granta519 mantle cell lymphoma cells (Wasik et al. 2011), or
AM251 and AM630 in OCM-1A and Colo 38 melanoma cells (Scuderi et al. 2011). Taken
together, these studies demonstrate that cannabinoids inhibit tumor cell growth in a cannabinoid
receptor-independent manner in certain systems. One caveat is that these studies did not
assess other cannabinoid sensitive targets such as GPR55, peroxisome-proliferator activated
receptors and Transient receptor potential-cation-channel subfamily V member 1 (TRPV1),
19

which could explain some of these effects. The observation of an as of yet unidentified third
cannabinoid receptor characterized by agonist stimulated [35S]GTPγS binding in CB1 mouse
knockout brains, could provide another possible explanation for the cannabinoid-independent
inhibition of cancer cell growth (Breivogel et al. 2001; Nguyen et al. 2010).

GPR55
GPR55 is an orphan GPCR that has been to be shown sensitive to cannabinoids such as
abnormal cannabidiol, THC, 2-arachidonoylglycerol, and anandamide by using complementary
assays. These assays include: a β-arrestin based luciferase reporter assay, a GPR55 activated
luciferase reporter assay and [35S]GTPγS binding assays in HEK-293T (HEK) cell over
expressing GPR55 (Johns et al. 2007; Yin et al. 2009). However, further research suggested
that GPR55 is actually a lysophosphatidylinositol receptor with cannabinoid sensitivity (Oka et
al. 2007). Unlike CB1 and CB2, GPR55 mediated effects on cancer were consistently linked to a
pro-cancer phenotype. Andradas et al. (2011) reported that expression of GPR55 in human
tumors was correlated with decreased patient survival, overexpression of GPR55 in HEK,
EVSA-T and T98G cells increased growth rates, and GPR55 knockdown decreased growth
rates in EVSA-T and T98G cells. The Pineiro et al. 2011 study further supports a GPR55 procancer phenotype by showing that GPR55 is expressed in PC-3 (prostate) and OVCAR3
(ovarian) tumor cells, and that GPR55 downregulation with siRNA decreases cell growth
compared to scrambled control siRNA. Lastly, GPR55 knockout mice showed decreased tumor
formation after treatment with the carcinogen DMBA, indicating that GPR55 plays a role in
tumor development (Perez-Gomez et al. 2012).
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Peroxisome-proliferator activated receptors
Peroxisome-proliferator activated receptors (PPAR) are a group of three (α, δ and y)
nuclear receptors involved in metabolism and cell differentiation (Schoonjans et al. 1996;
Spiegelman 1998). Activation of PPARα by fibrate drugs treats high cholesterol (Schoonjans et
al. 1996), and activation of PPARγ by thiazolidinedione drugs treats insulin insensitivity in
diabetes (Spiegelman 1998). Recent preclinical studies have found that PPARγ is expressed in
MCF-7 breast cancer cells (Nwankwo et al. 2001), and continuous treatment with the selective
PPARy agonist troglitazone inhibited MCF-7 cell growth (Yin et al. 2001). Treatment with WIN2
in HepG2 hepatoma cells was found to induce apoptosis in a PPARγ dependent manner as
demonstrated by blockade of the effect by the PPARγ selective antagonist GW9662 (Giuliano et
al. 2009). Gene reporter (O’Sullivan et al. 2007) and antagonist studies (Mestre et al. 2009)
have demonstrated that WIN2 can function as an activator of PPARγ. Cannabinoid-induced
inhibition of cancer through PPARy is supported by studies from Vara et al. (2013), where
GW9662 also blocked the antiproliferative effects of both THC and JWH-015 in HepG2 cells.

Transient receptor potential-cation-channel subfamily V member 1
TRPV1 is a non-selective cation channel identified as the site of action for capsaicin
(Caterina et al. 1997). It has also been implicated in the sensory detection of high heat stimulus
(Caterina et al. 2000). AEA was later found to be a full agonist for TRPV1 based on comparison
to capsaicin in electrical current measurements using HEK-293 cells transfected with TRPV1
(Smart et al. 2000). TRPV1 is expressed on some cancers but its role in growth is uncertain. For
example, TRPV1 mRNA is found abundantly in MCF-7 cells (Ligresti et al. 2006), but the
TRPV1 agonist capsaicin has mixed growth inhibitory effects in MCF-7 cells ranging from
minimal (Tuoya et al. 2006) to significant (Thoennissen et al. 2010). Furthermore, these studies
do not link actions of capsaicin to TRPV1 either genetically or pharmacologically. Conversely,
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the TRPV1 antagonist capsazepine sensitizes HCT116 colon cells to tumor necrosis factorrelated apoptosis-inducing ligand (TRAIL) induced apoptosis, which argues for a protective
action of TRPV1 in some cancers (Sung et al. 2012), but again capsazepine mediated actions
were not linked to TRPV1 either genetically or pharmacologically.

Anandamide and fatty acid amide hydrolase
AEA was first identified as an endogenous cannabinoid by Devane et al. (1992) and
AEA levels were found to be regulated by the degradative enzyme fatty acid amide hydrolase
(FAAH; Deutsch et al. 1993). Treatment with AEA has been shown to inhibit the growth of
numerous cancer cell lines including MCF-7 (breast), MDA-MB-231 (breast), Mz-ChA-1 (biliary),
HCT116 (colon) and CaCo-2 (colorectal), (Melck et al. 2000; Laezza et al. 2006; DeMorrow et
al. 2008; Patsos et al. 2010; Liao et al. 2011). Interestingly, MCF-7 cells have been shown to
express FAAH. This FAAH expression might be a mechanism to protect the MCF-7 cells from
the endogenously synthesized ligand AEA (Takeda et al. 2008). More work is required to prove
this hypothesis however.

2-Arachidonoylglycerol and monoacylglycerol lipase
The

fatty

acid

derivative

2-Arachidonoylglycerol

(2-AG)

was

the

second

endocannabinoid discovered when Seguira et al. (1995) used 2-AG to competitively inhibit the
radiolabelled cannabinoid receptor agonist CP55,940. Later research further confirmed 2-AG as
an endocannabinoid, when selective inhibition of 2-AG hydrolysis increased 2-AG levels in the
brain and elicited cannabimimetic effects (Makara et al. 2005). In cancer the actions of 2-AG
has not been as extensively studied as other cannabinoids, but the endocannabinoid is capable
of inhibiting C6 glioma cell growth dose-dependently (Jacobsson et al. 2001). Additionally,
increasing 2-AG levels by inhibiting its degradation or administering a stable 2-AG analog such
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as noladin ether inhibits invasion of PC-3 and DU-145 prostate cells through matrigel in
transwell plates (Nithipatikom et al. 2004).
The primary degradative enzyme responsible for regulating the levels of 2-AG is
monoacylglycerol lipase (MAGL; Dinh et al. 2012), and to a lesser extent ABHD6 and ABHD12
(Blankman et al. 2007; Marrs et al. 2010). In addition to regulating 2-AG, MAGL was implicated
as a regulator of a network of monoacylglycerol fatty acids in cancer cells by preventing their
accumulation. The fatty acids in this network were linked to anti-cancer effects including growth
and invasion inhibition (Nomura et al. 2009). Pharmacological inhibition using JZL184 and
genetic knockdown using shRNA increased expression of four monoacylglycerols in C8161
melanoma cells and SKOV3 ovarian cancer cells. In both melenoma and ovarian cancers, the
genetic knockdown of MAGL decreased cancer cell survival, migration and invasion in vitro;
treatment with JZL184 decreased in vivo tumor growth. Overexpression of MAGL in MUM2C
melanoma cells had opposite effects with decreased monoacylglycerol presence in the cells,
increased migration and invasion in vitro, and increased in vivo tumor growth (Nomura et al.
2009).

Cannabinoid signaling in cancer
Decades of research have led to a robust understanding of the upstream signaling
events from CB1 and CB2 receptors in their respective tissues, neuronal and immune. These
processes are well characterized in reviews such as Howlett et al. (2002). The same level of
attention, however, has not been paid to upstream cannabinoid signaling in cancer. It appears in
large part that researchers assume the activation of a cannabinoid receptor in a cancer cell
results in similar upstream signaling events as would be observed in a non-neoplastic tissue.
While it is not necessarily incorrect to make this assumption, it cannot be stated definitively that
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this is true and future research is still needed. Current research has, however, led to a number
of novel findings related to downstream cannabinoid signaling events in cancer cells.
Carracendo et al. (2006) identified that CB1 receptor activation by THC leads to
modulation of ceramide signaling in U87-MG glioblastoma cells to mediate the antiproliferative
actions observed with cannabinoid treatment. This ceramide signaling was later tied to the
induction of endoplasmic reticulum stress, autophagy and apoptotic cell death in the same cell
line by Salazar et al. (2009). Dando et al. (2013) identified that synthetic cannabinoids modulate
AMPK signaling to affect cell survival through modulation of energy pathways in multiple
pancreatic cancer cell lines. Additionally, in the cervical cancer model, HeLa cells, a stable
analog of AEA was shown to induce apoptosis through prostaglandin production in a
cyclooxygenase-2 dependent manner (Eichele et al. 2009). These examples of cannabinoid
signaling in cancer are meant to exemplify that cannabinoid actions can be highly diverse in
nature depending on the model and cannabinoid used, but since this document focuses on
cannabinoid actions in breast cancer, the following section will explain major findings of how
cannabinoid associated signaling events in breast cancer cells inhibit the growth of these breast
cancer models.

Cannabinoid actions in breast cancer

Antiproliferative actions - Anandamide
In studies by De Petrocellis et al. (1998), AEA was shown to dose-dependently decrease
the number of both EFM-19 and MCF-7 breast cancer cells. AEA elicited effects were attributed
to growth inhibition instead of cell death in both cell lines based on time course studies and a
decrease in [3H]thymidine incorporation. EFM-19 cells were shown to be capable of hydrolyzing
AEA suggesting that a metabolite of AEA, instead of AEA itself, could inhibit EFM-19 cell
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growth. Comparison of AEA and its primary metabolite arachidonic acid (AA) showed that AA
was significantly less capable at inhibiting EFM-19 cell growth than AEA, and there was also no
significant difference in growth inhibition when AEA was compared to its non-hydrolyzable form
methanandamide (MAEA). Dose-dependent inhibition of EFM-19 cells by other cannabinoids,
HU-210 and 2-AG, suggested that AEA inhibition of EFM-19 cell growth was cannabinoid in
nature, and blockade of AEA growth inhibition by SR1 confirmed AEA mediated effects were
CB1 receptor mediated. AEA suppression of cell cycle progression was attributed to prolactin
growth signaling because of dose-dependent inhibition of prolactin induced growth stimulation in
EFM-19 cells by AEA. AEA antagonism of prolactin was also antagonized by SR1.
Melck et al. (2000) studied the AEA mechanism of growth inhibition in MCF-7 cells as an
extension of De Petrocellis et al.’s work. As in EFM-19 cell, MCF-7 cells showed dosedependent growth inhibition by AEA. Growth inhibition by AEA was again demonstrated to be
cannabinoid in nature when the cannabinoids HU-210, methanandamide and 2-AG elicited
similar levels of growth inhibition, and SR1 blocked AEA mediated antiproliferative effects.
Melck et al. went on to show that the CB2 selective antagonist, SR2, did not block AEA induced
antiproliferation, further confirming a CB1 receptor-dependent effect. Melck et al. hypothesized
that AEA was antagonizing MCF-7 growth by decreasing nerve growth factor (NGF) signaling
through downregulation of NGF associated Trk receptors. This hypothesis was based on a
correlation between AEA growth inhibition, AEA antagonism of the growth stimulation from
exogenously administered NGF and AEA induced downregulation of Trk receptors. These two
papers, De Petrocellis and Melck et al., are the first demonstration that cannabinoids are
capable of eliciting multiple mechanisms of action to inhibit breast cancer cell growth depending
on the model.
Laezza et al. (2006; 2010) continued Melck et al.’s work in MCF-7 cells using the
synthetic analog of AEA, MAEA. MAEA was shown to decrease cAMP response element
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binding protein phosphorylation and the authors indicated that this is a likely explanation for the
decreased expression of HMG-CoA reductase after MAEA treatment. HMG-CoA reductase is
integral to the synthesis of mevalonate or mevalonic acid (MVA). Exogenous administration of
MVA to MCF-7 cells rescued the cells from MAEA mediated antiproliferative effects.
Radiolabelled MVA was incorporated into proteins and immunoprecipitation studies showed that
proteins containing MVA were decreased after MAEA treatment, one such protein being RAS
which is well known to have mitogenic effects. MVA incorporation into RAS allows it to
translocate to the membrane. Under MAEA treatment, RAS levels in the membrane decreased
while cytosolic RAS increased, and exogenous administration of MVA inhibited this effect.
Based on the well-known RAS mediated pro-proliferative actions in cancer cells, the decrease
of active RAS caused by MAEA inhibition of MVA synthesis was cited as the explanation for
MAEA induced cell cycle arrested, p21 accumulation and Chk1 phosphorylation (Laezza et al.
2006; 2010).

Antiproliferative actions - THC
THC was shown to have antiproliferative actions against multiple breast tumor cell lines
including MCF-7, MDA-MB231, EVSA-T and SkBr3. THC mediated inhibition of EVSA-T cells is
CB2 dependent based on SR2 but not SR1 antagonism of THC, and the expression of CB2 but
not CB1 in EVSA-T cells. THC mediated inhibition of EVSA-T cells was attributed to G2-M cell
cycle arrest quantified by propidium iodide staining, and a simultaneous occurrence of apoptosis
quantified by sub-G1 population, annexin V/PI staining and caspase 3 activation. Western
blotting showed an increased expression of p21 and a decrease in Cdc2, which explains the cell
cycle arrest. Apoptosis was associated with decreased expression of the anti-apoptotic protein
survivin which was also confirmed by western blotting. Survivin is also known to be stabilized by
Cdc2 and the decrease of Cdc2 under THC treatment would explain the decrease in survivin
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levels. THC invokes translocation of the transcription factor, JunD, to the nucleus of the cell.
Knockdown of JunD prevents THC downregulation of Cdc2 and rescues EVSA-T cells from
THC treatment; genetic overexpression of Cdc2 also rescues EVSA-T cells from THC. Together
these studies show that THC activates CB2 in EVSA-T cells to cause JunD translocation leading
to downregulation of Cdc2 which results in cell cycle arrest and apoptosis (Caffarel et al 2006;
2010).

A study by von Beuren et al. (2008) showed that THC treatment in MCF-7-AR1 cells
antagonized estradiol stimulated growth, but THC did not inhibit growth of MCF-7-AR1 cells
alone. THC treatment in parent MCF-7 cells did however dose-dependently decrease viable cell
number. This finding is partially supported by Takeda et al. (2008; 2009) where THC
antagonized the growth stimulating effects of estradiol in MCF-7 cells. Surprisingly, the Takeda
et al. studies also characterized a growth stimulating action of THC in MCF-7 cells, which is
somewhat paradoxical when compared to growth inhibitory effects of THC in the previously
mentioned study by von Beuren et al. A review of the methods used between the studies
revealed no obvious differences that explain growth stimulating and growth suppressing effects
in the same cell line from the same drug.

Antiproliferative actions - CBD
Ligresti et al. (2006) examined the antiproliferative effects of various phytocannabinoids
across a spectrum of breast cancer cell lines. The major component of their study however
focused on antiproliferative effects of cannabidiol (CBD) in MDA-MB-231 cells, which were
demonstrated both in vitro and in vivo. CBD antiproliferation was attributed to a modest
induction of apoptosis elicited through the increased influx of calcium and the generation of
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ROS. McCallister et al. (2007; 2011) also confirmed the antiproliferative effects of CBD in MDAMB231 cells, and that the anti-oxidant α-tocopherol protected MDA-MB231 cells from ROS
produced by CBD treatment, similar to what was shown in Ligresti et al. Overexpression of the
transcription factor Id-1 rescued MDA-MB231 cells from CBD treatment confirming the
hypothesis that CBD downregulation of Id-1 demonstrated through western blotting mediates
the inhibition of MDA-MB231 cell growth. Anti-tumor effects of CBD were extended to the whole
animal using the 4T1-Balb/c syngeneic model (McCallister et al. 2007; 2011).
CBD actions in MDA-MB231 cells were again expanded in Shrivastava et al. (2011).
This study confirmed ROS species involvement using the anti-oxidant α-tocopherol, which was
demonstrated in both studies from Ligresti and McCallister et al. Shrivastava et al. also
confirmed CBD induction of apoptosis shown by Ligresti et al. Novel observations from
Shrivastava et al. highlight the induction of autophagy alongside apoptosis under CBD
treatment. In a time- and dose-dependent manner, both apoptosis (annexin V staining or PARP
cleavage) and autophagy (LC3 cleaved western blotting) increased in parallel under CBD
treatment. Administration of the autophagic inhibitor bafilomycin or the caspase inhibitor zVAD
to MDA-MB231 cells treated with CBD show modest changes in cell death. No other
experiments were conducted to evaluate the interaction between apoptosis and autophagy,
leaving conclusions unclear if these two processes of autophagy and apoptosis are working
together or separately to mediate CBD induced antiproliferative actions. CBD inhibition of AKT
phosphorylation was also hypothesized to play a role in the antiproliferative effects of CBD
based on a correlation between CBD treatment and a decrease of AKT phosphorylation
(Shrivastava et al. 2011).
Additional observations from the above studies show that CBD inhibited MDA-MB231
cell growth independent of cannabinoid receptors based on the use of cannabinoid receptor
antagonists (Ligresti et al. 2006; Shrivastava et al. 2011). This is not surprising since CBD has
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extremely poor affinity for CB1 (Ki=4.3 μM) and CB2 (Ki=1.2 μM) (Showalter et al. 1996). Also,
Shrivastava et al. demonstrated that CBD had a lower efficacy at inhibiting growth of the nontransformed MCF-10a breast epithelial cells than the MDA-MB231 breast cancer cells, which
shows a potentially cancer selective effect for CBD treatment in MDA-MB231 cells.

Antiproliferative actions - synthetic cannabinoids
Other

studies

have

linked

synthetic

cannabinoids

(WIN2

and

JWH-133)

to

antiproliferative effects in cancer as well (Qamri et al. 2009; Caffarel et al. 2010). WIN2 and
JWH-133 inhibited MDA-MB231 cell growth both in vitro and in vivo. In vitro studies found that
both CB1 and CB2 mRNA were expressed in MDA-MB231 cells, and in vivo studies show that
both the CB1 selective antagonist AM251 and the CB2 selective antagonist SR2 reduced WIN2
inhibition of tumor volume. JWH-133 is a CB2 selective agonist, therefore only SR2 was used to
antagonize its effects. This indicates that both CB1 and CB2 are involved in the antiproliferative
actions of cannabinoids in MDA-MB231 cells. WIN2 and JWH-133 inhibition of MDA-MB231
proliferation was attributed to the induction of apoptosis quantified by a sub-G1 population from
cell cycle analysis (Qamri et al. 2009).
Caffarel et al. 2010 further demonstrated the antiproliferative effects of JWH-133 using
an ErbB2 based genetic model of tumor development. JWH-133 and THC suppressed growth of
tumors in vivo as well as suppressed cell viability in vitro using N202.1A cells. Caffarel et al.’s
histological analysis of human tumor samples showed a correlation between ErbB2 positive
tumors and CB2 receptor expression indicating a connection between the two receptors; based
on this correlation, JWH-133 and THC were tested with the antagonists SR2 and SR1. Only
SR2 inhibited in vitro tumor growth indicating CB2 dependent antiproliferative effects. Caffarel et
al. (2010) also observed a decrease in p-AKT when N202.1A breast tumor cells were treated
with both THC and JWH-133. Overexpression of AKT in N202.1A cells also prevented both THC
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and JWH-133 from inhibiting cell growth both in vitro and in vivo, implicating AKT signalling in
the CB2 dependent actions of THC and JWH-133.

Anti-invasive and anti-metastatic cannabinoid actions
In addition to characterizing the antiproliferative effects of synthetic cannabinoids, Qamri
et al. 2009 and Caffaral et al. 2010 also characterized the anti-invasive and anti-metatstatic
effects of WIN2, JWH-133 and THC. WIN2 and JWH-133 decreased the in vitro migratory action
and the in vivo formation of metastatic lung nodules by MDA-MB231 cells (Qamri et al. 2009).
Additionally, JWH-133 and THC decreased the number of blood vessels per tumor and the
number of metastatic nodules in genetically derived breast carcinomas. Decreases in number of
blood vessels and metastatic nodules indicate an anti-angiogenic and anti-invasive action for
cannabinoid treatment, which is likely explained by JWH-133 and THC mediated effects on
matrix metalloproteases (MMP). Both JWH-133 and THC in Caffarel et al. decreased
expression of the pro-invasive MMP2 and increased expression of the anti-angiogenic MMP9.
MAEA also inhibits invasion, migration and metastasis of MDA-MB231 cells both in vivo
and in vitro. Antagonism of MAEA elicited anti-invasive actions with SR1 demonstrates a CB1
component to this observation, although CB2 antagonists were not assessed (Grimaldi et al.
2006). These anti-invasive effects were linked to MAEA-mediated decrease of RHOA, which is
known to be involved in actin rearrangement for cell motility. MAEA decrease of RHOA was also
shown to be CB1 dependent using the CB1 antagonist SR1. MVA rescued the downregulation of
RHOA and anti-invasive effects demonstrated by MAEA (Laezza et al. 2008), and MVA rescue
of RHOA downregulation connects MAEA associated anti-invasive actions in MDA-MB231 cells
to the MAEA mediated antiproliferative effects in MCF-7 cells discussed in detail above (Laezza
et al. 2006; 2010). A cannabinoid constituent of marijuana, cannabidiolic acid, was also able to
inhibit MDA-MB231 invasion measured in vitro using transwell migration and the wound healing
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assay, and like Laezza et al. (2008), this cannabidiolic acid treatment also induced a
downregulation of RHOA (Takeda et al. 2012).
A unique observation by Nasser et al. (2011) showed that the CB2 selective agonist
JWH-015 inhibited CXCR4 associated migration in MCF-7/CXCR4, MDA-MB231 (SCP2) and
NT 2.5 breast cancer cells, which overexpress CXCR4. Migration was quantified using the
transwell migration and wound healing assays. The CXCR4 agonist CXCL12 enhanced
migration in both assays compared to vehicle. Treatment with JWH-015 and CXCL12 showed
less migration compared to treatment with vehicle and CXCL12 in both assays but JWH-015
effects on migration in the absence of CXCL12 were not quantified. Absence of data for the
JWH-015 and vehicle control prevents the conclusion that JWH-015 is antagonizing CXCR4
mediated migration since JWH-015 might be suppressing migration in general. Regardless,
JWH-015 was shown to have some effect on migration in the MCF-7/CXCR4, MDA-MB231
(SCP2) and NT 2.5 cell lines.

Summary, hypothesis and goals of the following studies

The research presented in section 1 of this document has proven that cannabinoids have
the capacity to inhibit the growth of breast cancer cells through a variety of mechanisms. The
goals of the following work, was to evaluate the antiproliferative effects of cannabinoids alone
and in combination with established breast cancer therapies, as well as attempt to elucidate
mechanism(s) for the effects of these treatments. Section 3 of the document will present further
information to support the hypothesis of these studies, which was that cannabinoid agonist
treatment in breast cancer cells would augment radiation and/or adriamycin treatments to
enhance the antiproliferative effects of either therapeutic strategy through an autophagic
mechanism.
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Each section of this document will be presented with the necessary background
information specifically pertinent to the aims of that section, followed by results and ending with
a brief discussion. The first results section (section 3 of the document) will address cannabinoid
interactions with chemotherapy and radiotherapy. The second results section (section 4) will
investigate the mechanism(s) of breast cancer cell growth inhibition elicited by cannabinoid and
radiation combinations, and finally the third results section (section 5) will examine receptor
involvement for the cannabinoid treatment. The discussion section (section 6) presented at the
end of the document aims to connect these three research aims, demonstrate the interaction of
each respective project, and summarize how each contributes to the overall conclusions made
from this body of research.
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Section 2
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Materials and Methods

Cell line maintenance
MCF-7, MDA-MB231, and MCF-10a cells were obtained from ATCC (Manassas, VA).
Luciferase transfected 4T1 cells were obtained from Caliper (Hopkinton, MA). MCF-7, MDAMB231 and 4T1 cells were cultured in RPMI media (Invitrogen, Grand Island, NY) with 1%
penicillin/streptomycin solution, 5% fetal bovine serum and 5% bovine calf serum. MCF-10a
cells were cultured in DMEM/F12 media (Invitrogen) supplemented with 1% pen/strep solution,
10% horse serum, insulin 10 ug/ml, cholera toxin 100 ng/ml, EGF 20 ng/ml, and hydrocortisone
500 ng/ml. For studies under low serum conditions, cells were cultured in RPMI with 1%
pen/strep, 0.05% fetal bovine serum, and 0.05% bovine calf serum. For studies utilizing
estradiol, MCF-7 cells were cultured in phenol red free IMEM media (Invitrogen) supplemented
with 1% pen/strep solution and 10% fetal bovine serum.

Drugs and reagents
WIN55,212-2, WIN55,212-3, chloroquine diphosphate salt, staurosporine, CP55,940,
glutathione, methanandamide, n-acetylcysteine, nabilone, pioglitazone, bezafibrate, capsaicin,
adriamycin, paclitaxel AM251, capsazepine, GW9662, and estradiol were purchased from
Sigma (St. Louis, MO). CBD and THC were generously provided by NIDA (Bethesda, MD).
AM630 was purchased from Enzo Life Sciences (Farmingdale, NY). Pravadoline, JWH-015 and
SEW2871 were purchased from Caymen Chemical (Ann Arbor, Michigan). Ketamine and
xylazine were obtained from Butler Schein Animal Health. S1P was a gift from the laboratory of
Dr. Sarah Spiegel (Virginia Commonwealth University).
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Drug treatments
All treatments with cannabinoids, cannabinoid antagonists, capsaicin, capsazepine,
pioglitazone, GW9662, bezafibrate, S1P, SEW2871 and estradiol were initiated with a 24 h
exposure period, after which the drug-containing media was aspirated, the cells were washed
with phosphate-buffered solution (PBS), and replenished with fresh media. Radiation was
administered at the same time as drug, unless otherwise indicated. Exposure to drug
antagonists was coincidental with the receptor agonists. Adriamycin (doxorubicin) was used at 1
μM with an exposure time of 2 h. Paclitaxel was used at 0.5 μM with an exposure time of 24 h.
For autophagy inhibition, chloroquine (5 μM) was administered to cells for the duration of the
experiment. For ROS inhibition, N-acetylcysteine and glutathione were administered to cells 24
h before initiation of drug treatment, and maintained throughout drug treatment for a total of 48
h. H2O2 was administered with drug and radiation as a positive control for ROS mediated cell
death. Media treated with H2O2 was removed after 24 h. In experiments under low serum
conditions, drugs were added to the low serum media and low serum media was administered
to cells for 24 h. After 24 h the low serum media and drugs were removed and replaced with
regular media absent of drug. In studies involving estradiol, the cells were maintained in phenol
red free IMEM media through the course of the experiment. All experimental results were
analyzed at 96 h, unless otherwise indicated. Cell counts for 4T1 cells were determined at 48 h
due to their rapid growth rate.

Cell count methods –
Trypan blue viable cell number - Cells were plated into six well plates MCF-7 and
MDA-MB231 cells (50,000 cells/well); 4T1cells (100,000 cells/well). Viability was determined
based on trypan blue exclusion using a hemocytometer or Invitrogen Countess automated
counter.
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Crystal violet assay - Cells were plated into 96 well plates and allowed to adhere
overnight MCF-7 and MDA-MB231 lines (5,000 cells); 4T1 cells (10,000 cells). After 96 h, cells
were washed with PBS, fixed with methanol and stained with a 0.5% solution of crystal violet in
25% methanol. Samples were solubilized with a 0.1M Na-Citrate solution in 50% ethanol before
absorbances were measured at 540 nm using a microplate reader.

Flow cytometry –
Annexin V and propidium iodide - Cells were harvested at the indicated time points
and washed twice with PBS prior to centrifugation at 500xg in a 4°C 5810 R Eppendorf
centrifuge. Annexin V and PI were obtained from BD Bioscience and diluted in binding buffer
according to the manufacturer’s instructions before being added to cells. Samples were
analyzed by flow cytometry at 520 nm for FITC labeled annexin V and 617 nm for PI.
γH2AX - Both adherent and non-adherent cells were collected and pelleted at indicated
time points using a 4°C 5810 R eppendorff centrifuge at 500xg. Samples were fixed in
formaldehyde (3.7%) in PBS for 10 min at 37°C before being chilled on ice and re-pelleted.
Fixative was removed, cells were permeabilized using methanol, the methanol was removed
and cells were washed twice with 5 mg/ml bovine serum albumin (BSA) in PBS, and then
blocked using the BSA solution for 10 min at room temperature. γH2AX-FITC conjugated
antibody was added at a dilution of 1:200 in 200 µl per sample followed by incubation for 60 min
at room temperature. Cells were washed with BSA solution twice more before being
resuspended in PBS. Measurements were performed by flow cytometry at a wavelength of 520
nm.
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Cell staining –
Cell staining was used to identify senescent cells (β-galactosidase), nuclear morphology
(DAPI) and autophagic vesicles (acridine orange).
β-galactosidase (pH 6.0) - As described in Biggers et al. (2013), cells were plated into 6
well plates at 10,000 cells/well. At appropriate time points, cells were washed twice with PBS
and fixed with 2% formaldehyde/0.2% glutaraldehyde for 5 min. The cells were washed again
with PBS and stained with a solution of 1 mg/mL 5-bromo-4-chloro-3-indolyl-b-galactosidase in
dimethylformamide (20 mg/mL stock), 5 mM potassium ferrocyanide, 5 mM potassium
ferricyanide, 150 mM NaCl, 40 mM citric acid/sodium phosphate, pH 6.0 and 2 mM MgCl2.
Following overnight incubation at 37ºC, the cells were washed twice with PBS and the images
of representative microscopic fields were captured on an Olympus 1 x 70 inverted microscope
(Olympus America, Inc., Melville, NY). Senescent cells were quantified manually based on blue
staining and reported as a percent of the total population.
4',6-diamidino-2-phenylindole (DAPI) - As described in Biggers et al. (2013), at the
indicated time points both adherent and nonadherent cells were harvested and centrifuged at
1,500 rpm for 3 min. A dilution of 20,000 cells in 200 μl of PBS per slide was prepared, and cells
were spun at 500xg for 5 min (Shandon Cytospin 4, Thermal Electron Corp). Slides were
refrigerated until ready for staining. Cells were fixed with 4 % formaldehyde in PBS for 10 min at
room temperature and then washed with PBS twice for 5 min at room temperature. A 1:1,000
dilution was prepared for Vectashield:Dapi, and each slide was mounted with 10 μl of the
solution. Coverslips were sealed using clear nail polish, and photographs were taken using an
Olympus 1 x 70 inverted microscope (Olympus America, Inc., Melville, NY). Slides were stored
at 4°C, and three fields per condition were evaluated.
Acridine orange - As described in Biggers et al. (2013), cells were plated at a density of
2 x 10⁵ cells per 6-well plate and allowed to adhere overnight. After drug treatment, drug was
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removed and cells were washed with PBS. Cells were stained with acridine orange (1 μg/mL)
for 15 min. At selected time points, cells were stained for 10 min, the stain was removed and
cells were washed with PBS four times before fresh media was added to the wells. Photographs
were taken using an Olympus 1 x 70 inverted microscope (Olympus America, Inc., Melville, NY).
Staining was visualized at a fluorescence wavelength of 500 nm. All comparisons were made at
identical magnifications.

RT-PCR
Total RNA was extracted from cells by using Trizol Reagent (Gibco BRL Technologies,
USA), and reverse-transcribed with iScript cDNA Synthesis Kit (BIO-RAD, USA). The cDNA
obtained from each sample was used as template for PCR using KAPA Mouse Genotyping Kit
(KAPA Biosystems, USA). The primer was synthesized by Invitrogen (USA) and primer
sequences were as follows: CB1 forward- GACCATAGCCATTGTGATCG, CB1 reverseGGTTTCATCAATGTGTGGGA, CB2 forward- GACCGCCATTGACCGATACC, CB2 reverseGGACCCACATGATGCCCAG, TRPV1 forward- CTCACCAACAAGAAGGGAATG, TRPV1
reverse- AGGTCGTACAGCGAGGAGTG, PPARγ forward- ATGACAGCGACTTGGCAATA,
PPARγ

reverse-

GAGGACTCAGGGTGGTTCAG,

GPR55

forward-

CATCTCTCAGCCCTCTCAGC, GPR55 reverse- TTCTTCCTACAACACCAACAGA, Beta actin
forward- TGGGACGACATGGAGAAA, Beta actin reverse- CACAGCCTGGATAGCAACG. The
PCR program was as follows: 95 oC for 3 min; 35 cycles of 95 oC for 15 s, 58 oC for 15 s and 72
o

C for 20 s; 72 oC for 2 min. Primer sequences for CB1 and CB2 receptors were contributed by

Dr. Mary Abood of Temple University, Department of Anatomy and Cell Biology.
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Agonist stimulated [³⁵S]GTPγS binding –
Activation of G proteins by sphingosine-1-phosphate (S1P) and WIN55,212-2 (WIN2)
was quantified by agonist-stimulated [³⁵S]GTPγS binding assays.
Cell Harvesting - MCF7 cells were harvested and centrifuged before suspension in icecold membrane buffer (50 mM Tris-HCl, 3 mM MgCl 2 and 1 mM EGTA, pH 7.4). The cells were
homogenized using a Polytron homogenizer for 10 seconds, then centrifuged at 50,000xg at
4°C for 10 min. Membranes were resuspended in membrane buffer, and protein was
determined by the method of Bradford using 1 mg/ml bovine serum albumin (BSA) as the
standard. Membrane preparations were stored in aliquots at -80°C.
Membrane preparation - Frozen membrane samples were thawed on ice and were
homogenized in 50 mM Tris-HCl, 3 mM MgCl2, 0.2 mM EGTA, 100 mM NaCl pH 7.4 (assay
buffer) using a Polytron homogenizer for 10 seconds.

Homogenates were centrifuged at

50,000xg at 4°C for 10 minutes and resuspended in assay buffer. Membrane protein levels were
assessed via the Bradford method, using 1 mg/ml BSA as the standard (Bradford, 1976).
[35S]GTPγS Binding - Concentration-effect curves were generated by incubating the
appropriate concentration of membrane (10 µg protein) in assay buffer with 0.1% BSA, various
concentrations of S1P and/or WIN2, 30 μM GDP and 0.1 nM [³⁵S]GTPγS in 0.5 ml total volume.
Basal binding was assessed in the absence of agonist, and nonspecific binding was measured

in the presence of 10 μM unlabeled GTPγS. The reaction was terminated by filtration under
vacuum through Whatman GF/B glass fiber filters, followed by three washes with cold (4°C)
Tris buffer (50 mM Tris-HCl, pH 7.4). Bound radioactivity was determined by liquid
scintillation spectrophotometry at 95% efficiency for [35S] after extraction overnight in
Econo-Safe scintillation fluid.
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In vivo studies –
Animals and maintenance - Female Balb/c mice (Jackson Laboratory, Bar Harbor, ME)
weighing between 17 and 22 g (approximately 8-10 weeks of age at the start of the study) were
housed 4 per cage in a temperature controlled (20-22oC) vivarium approved by the American
Association for the Accreditation of Laboratory Animal Care. The mice were maintained on a 12
h light/dark cycle, with all experiments performed during the light cycle. Food and water were
available ad libitum. All experiments were approved by the Institutional Animal Care and Use
Committee at Virginia Commonwealth University in accordance with the Guide for the Care and
Use of Laboratory Animals.
Tumor growth - 4T1 cells were suspended into sterile PBS at 250,000 cells per ml. A
200 µl volume of the cell suspension was subcutaneously injected into the hind flank of Balb/c
mice. Tumors were permitted to stabilize for 24 h prior to treatment and allowed to grow for 1617 days, until evidence of necrosis was detected or the tumor burden exceeded 1 cm 3. Tumor
volume was assessed by caliper measurements by an investigator blinded to the experimental
conditions; tumor volume was calculated by the formula V=0.5(W(L2)). Radiation treatments
were given 24 h after injection of tumor cells. Irradiated animals were anesthetized using
ketamine (85 mg/kg) and xylazine (8.5 mg/kg) before being placed into a focused irradiation
chamber limiting exposure to the right hind quarter. 24 h after irradiation, drug treatments were
begun. Vehicle (ethanol, emulphor, and saline in a ratio of 1:1:18), WIN,212-2 (1, 5, or 10
mg/kg) or WIN,212-3 (5 mg/kg) were administered to mice twice weekly via intraperitoneal (i.p.)
injection. Adriamycin (5 mg/kg), used as a positive control, was administered once per week i.p.
for two total treatments.
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Statistics –
In vitro tests - All experiments were performed with 3-6 replicates. Two-way repeated
measures ANOVA was used to analyze radiation and drug treatments for individual treatment
effects and potential interactions between treatments. All two-way ANOVA comparisons were
done within time point. Paired T-test with a Bonferroni correction was used for individual
comparisons and to assess interactions of combination treatments. Standard paired T-tests
were used for validation of positive controls. Temporal studies utilized One way repeated
measures ANOVAs for two purposes 1) to assess growth inhibition within each time point by
comparison to vehicle and 2) to assess cell death by comparing an individual treatment across
time points. Dunnett’s post hoc test was used with One way repeated measures ANOVAs. All
data are displayed as mean+se.
In vivo tests - All animal studies utilized 8 mice per treatment group. A Two-way
ANOVA was used to analyze radiation vs. drug treatments within each time point to assess
interactions and main effects of drug. A T-test with a Bonferroni correction was used to assess
comparisons of combination + drug with the individual treatments. A One way ANOVA was used
to assess effects of individual treatments across time points. Dunnett’s post hoc test was used
for comparisons to baseline. All data are displayed as mean+se.
Criteria for augmentation and antagonism - Interactions between treatments were
evaluated using the following statistical criteria. Two way ANOVAs assess significant
interactions between treatments by requiring p<0.05 for interaction comparisons. If a significant
interaction was found then individual comparisons with a bonferroni corrected T-tests were used
to determine the type of interaction.
Using the bonferroni corrected T-test to assess augmentation. Studies will evaluate the
effects of two individual treatements (cannabinoid or cancer therapeutic) and then the
combination of the two treatments (cannabinoid + cancer therapeutic). If both individual
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treatments are significantly different from vehicle (p<0.05), then the combination treatment must
be significantly different when compared to the cannabinoid treatment (p<0.025) and the cancer
therapeutic treatment (p<0.025). If either of the individual treatments are not found significantly
different from vehicle by p<0.05, then the combination treatment must be significantly different
from vehicle (p<0.0166), cannabinoid treatment (p<0.0166) and the cancer therapeutic
treatment (p<0.0166). To demonstrate antagonism the combination treatment need only be
shown to significantly decrease antiproliferative action when compared to one or both of the
individual treatments (p<0.05).
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Section 3
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Characterization of cannabinoids in combination with ADR and radiation

Various studies have implicated a process known as autophagy in the antiproliferative
action of cannabinoids (Salazar et al. 2009; Shrivastava et al. 2011; Donadelli et al. 2011,
Dando et al. 2013). Autophagy was originally characterized in normal cells as a degradative
process used throughout the body in which intracellular autophagosomal structures are
generated that consume cellular materials such as mitochondria and endoplasmic reticulum for
the purposes of nutrient recycling, energy production or management of cellular stresses.
Autophagy has now been implicated in cancer cell treatment as either a novel cell death
mechanism, a precursor to growth inhibitory mechanisms or protection from treatment stress.
However, differences between death-promoting forms of autophagy and protective forms of
autophagy are poorly understood (Yang et al 2011, Mah et al. 2012, Leone et al 2013).
Cannabinoid and cancer research clearly links autophagy to antiproliferative action in
various publications. In Salazar et al. (2009), THC induced autophagy via activation of CB1 in
U87-MG glioblastoma cells. The cannabinoid receptor antagonist SR1 was used to confirm CB1
involvement and GFP-LC3 puncta formation and electron microscopic autophagosome imaging
confirmed autophagy induction. THC also induced apoptosis identified by active caspase 3
staining, annexin V/PI staining and antagonism by the pan-caspase inhibitor ZVAD. ATG1 and
ATG5 knockdown inhibited autophagy induction, prevented apoptosis induction and subsequent
cell death by THC treatment, demonstrating that THC induction of autophagy through CB1 leads
to the induction of apoptosis killing of glioblastoma cells. Studies further supported the
hypothesis of cannabinoid induction of autophagy. In MDA-MB231 cells cannabidiol induces
autophagy based on LC3 cleavage and electron microscopic autophagosome imaging. LC3
cleavage was prevented by the autophagy inhibitor bafilomycin (Shrivastava et al. 2011). In
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Panc1 cells, the cannabinoid agonists GW405833 and arachidonoyl cyclopropamide treatment
lead to autophagic induction quantified by LC3 cleavage, acridine orange staining and flow
cytometric quantification of MDC staining. (Donadelli et al. 2011, Dando et al. 2013).
Interestingly, data from the Gewirtz laboratory supports a hypothesis termed the
“autophagic switch”. This hypothesis suggests that autophagy can have multiple effects on cell
fate depending on the conditions of the system. The autophagic switch concept was initially
promoted in studies by Wilson et al. (2011) using radiation in ZR-75 breast cancer cells. This
hypothesis was then later expanded to radiation in MCF-7 breast cancer cells (Bristol et al.
2012), and then again extended to chemotherapeutic treatment in MCF-7 breast cancer cells
(Goehe et al. 2012).
The studies by Bristol et al. (2012) showed that 5x2 Gy of radiation-induced significant
levels of autophagy as measured by complementary assays including acridine orange staining,
RFP-LC3 puncta formation, autophagic vesicles imaged with electron microscopy and p62
degradation via western blot. Previous work has shown that senescence mediates growth
inhibition by radiation (Jones et al. 2005), and the work by Bristol et al. further supported this
finding by demonstrating (using cell viability and TUNEL assays) that radiation reduces
proliferative capacity in the absence of apoptosis. Blockade of autophagy by pharmacological
treatment with chloroquine or genetic knockdown of ATG5 further decreased viable cell number
and induced apoptotic cell death, demonstrating that manipulation of autophagy leads to a
transition from senescent growth arrest to cell death.
The study by Goehe et al. (2012) addressed the potential relationship between
autophagy and senescence by demonstrating that manipulation of autophagy induced by
adriamycin (ADR, also known as doxorubicin) treatment leads to a delay in the onset of
senescence. After 72 h, ADR was shown to induce a significant amount of senescence as
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measured by beta galactosidase staining, and a significant amount of autophagy as measured
by acridine orange staining, RFP-LC3 puncta formation, autophagic vesicles imaged with
electron microscopy and p62 degradation. Blockade of autophagy by chloroquine, 3methyladenine and ATG5 knockdown led to a decrease in autophagic signaling and delayed
senescence until 120 h post treatment. Consequently, these studies demonstrated that while
senescence could occur in the absence of autophagy, there was nevertheless a clear
connection between autophagy and the rate of ADR induction of senescence in MCF-7 cells.
This autophagic switch hypothesis presents the premise that autophagy is interconnected
with growth inhibitory and cell death processes, and that alterations in autophagy can alter how
the cell responds to various stressors. It is possible that the cited cannabinoid actions on
autophagy could alter autophagic mechisms in such a way as to enhance the antiproliferative
effect as was demonstrated in Bristol et al. 2012 and Goehe et al. 2012. This previous work
guided the generation of my hypothesis that cannabinoid agonist treatment in MCF-7 cells
would augment radiation and/or adriamycin treatments to enhance the antiproliferative effects of
either therapeutic strategy through an autophagic mechanism.
A primary aim of the studies presented in this section as well as the overall thrust of this
work was to evaluate the interaction of cannabinoid agonists in combination with either radiation
treatment or ADR treatment. These studies were performed in human (MCF-7 and MDA-MB231) and murine (4T1) breast cancer cells. For the purpose of assessing selectivity in
cancerous versus non-cancerous cells, the combination treatment was also evaluated in MCF10A cells, a model of normal breast epithelial cells. WIN55, 212-2 was the primary cannabinoid
evaluated in this work, and stereospecificity was determined utilizing its stereoisomer,
WIN55,212-3, which does not bind to cannabinoid receptors. The impact of radiation on breast
tumor cell growth was assessed in combination with a variety of cannabinoids, including THC,
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nabilone, CP55,940, methanandamide, cannabidiol (CBD), JWH-015 and pravadoline. In vivo
experiments were conducted using the 4T1-Balb/c syngeneic model to establish a WIN2 doseresponse curve and to test the interaction of WIN2 and radiation.

Cell lines

Bristol et al (2012) and Goehe et al (2012) used MCF-7 cells for their studies, and
cannabinoids including anandamide, cannabidiol, and THC have been shown to inhibit MCF-7
cell growth (De Petrocellis et al 1998, Legresti et al 2006, Caffarel et al 2006). These previous
studies provided the rationale for studying MCF-7 cells as the primary model for evaluating
cannabinoid treatment in combination with ADR and radiation and establishing and
characterizing any interaction. Once interactions were established in MCF-7 cells, other models
were used to assess generalization of combination treatments (MDA-MB231 and 4T1), test
combination effects in an appropriate in vivo model (4T1) or demonstrate selectivity of the
combination treatment for tumor cells (MCF-10a). A more detailed explanation and rationale for
the models chosen is provided below.

MDA-MB231 cells
MDA-MB231 cells are a p53 mutant cell line compared to the p53 wild type MCF-7
(Lacroix et al. 2006). p53 is commonly mutated in cancer with 31% of all cancers and ~23% of
breast cancers expressing this aberration. p53 gene mutations are also correlated with poor
prognosis, due to a collection of cancer promoting effects on cell growth, DNA repair,
tumorigenicity, cell death, angiogenesis and metastasis (Lacroix et al 2006, Walerych et al
2012). The frequency at which the p53 mutation is present in breast cancer and its effectiveness
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at enhancing pathology, makes it important to test the cannabinoid/cancer therapy combinations
against a p53 mutant model.
MDA-MB231 cells are also a triple negative breast cancer (TNBC) model, based on
absence of the estrogen receptor, progesterone receptor and Her2/neu receptor. Typically,
TNBC diseases are initially responsive to chemotherapy but resistant to hormone therapy. 78%
of TNBC patients show a response after initial therapy; however, this 78% also have faster rates
of recurrence than non-TNBC patients, show more frequent progression to metastasis than nonTNBC patients and have poorer 5 year survival rates than non-TNBC patients. Interestingly
though 22% of TNBC patients given treatment show complete disease elimination (CDE)
compared to the 11% CDE for non-TNBC disease. These 22% of TNBC patients also have a
higher percentage of 5 year survivors compared to non-TNBC patients that have CDE after
initial treatment (Liedtke et al. 2008). Based on this, combination therapies that can enhance
current treatment effectiveness could also translate to higher CDE rates and potentially lead to
greater 5 year survival rates in TNBC patients. Testing enhanced treatment effectiveness in a
TNBC model would require the use a model that is already responsive to our selected therapies
of radiation, ADR and cannabinoids.
MDA-MB231 cells have been demonstrated to be such a model. 10 gray (Gy) radiation
induces a G2 cell cycle arrest at early time points followed by induction of apoptosis quantified
by TUNEL staining and accumulation of a significant fraction of the cell population in the sub-G1
phase. Decreases in MDA-MB231 survival from radiation treatment persisted to 14 days (Jones
et al 2005). 2μM ADR in MDA-MB231 cells induces delayed apoptosis as quantified by TUNEL
staining (Elmore et al. 2002), leaving a small surviving fraction in senescent growth arrest
quantified by β-galactosidase activity (Di et al. 2009). The cannabinoids WIN55,212-2 and JWH133 were shown to inhibit in vitro cell viability and in vivo tumor growth of MDA-MB231 cells
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(Qamri et al. 2009), and likewise the phytocannabinoid, cannabidiol (CBD), decreased cell
viability via apoptosis as quantified by annexin V positive staining (Shrivastava et al. 2011).

4T1 cells
Cannabinoids and autophagy have immune related effects in tumor treatment that
become relevant when studies are moved in vivo (McKallip et al. 2005, Michaud et al. 2011).
For example, McKallip et al. (2005) showed that THC suppresses the antitumor immune
response in mice, which enhanced tumor growth. When Balb/c mice were injected with nonviable 4T1 cells they developed protection from tumor growth when later challenged by injecting
viable 4T1 cells, but THC suppressed this protection after the injection of non-viable 4T1 cells.
Furthermore, treatment with THC increased the number and size of 4T1 metastatic nodules in
lung of Balb/c mice compared to vehicle, while this did not occur in (immune-suppressed) SCID
mice. If cannabinoid treatments in these studies elicit similar suppression of the anti-tumor
immune response it could limit the effectiveness of a cannabinoid/cancer therapy combination
approach.
Michaud et al. (2011) showed that immune function is necessary for autophagy inducing
chemotherapies in vivo. CT26 colon cells treated with mitoxantrone (MTX) in vivo and in vitro
induced autophagy quantified by LC3 cleavage. Inoculating mice with CT26 cells treated with
MTX in vitro causes 80% protection from tumor development when mice are later challenged
using healthy/untreated CT26 cells. However, knockdown of the autophagy genes ATG5 and
ATG7 in CT26 cells blocks MTX mediated induction of autophagy, and when these knocked
down CT26 cells are treated with MTX in vitro and incoculated into mice, the mice show ~1535% decrease in protection from tumor development when challenged using healthy/untreated
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CT26 cells. These studies demonstrate that autophagy is relevant to some extent in signaling
the immune system after MTX treatment. If the cannabinoid/cancer therapy combination
treatment interact via autophagy as hypothesized, then an immune competent animal would be
required to detect this effect in vivo. 4T1 cells are a murine derived breast cancer model that
can be implanted into an inbred Balb/c mouse with normal immune function without incurring
unwanted graft host interactions (Aslakson et al. 1992).

MCF-10A cells
When augmenting growth inhibitory or cytotoxic effects of cancer therapies through the
use of other agents there is always a concern that this augmentation will extend to noncancerous tissues enhancing the toxic side-effects of these therapies. MCF-10A cells are a cell
line derived from the immortalized breast epithelial cell line MCF-10 (Soule et al. 1990), and
could be used for screening augmentation of toxicities in the cannabinoid/cancer therapy
combination treatments. A similar idea from Shrivastava et al. (2011) used the cell viability
assay to show that cannabidiol had greater growth inhibitory effects in MDA-MB231 cells than
MCF-10A cells demonstrating that cannabidiol toxicities do not transfer to all cell types equally.
Similar comparisons between MCF-7 and MCF-10A would offer insights into the effects of
cannabinoids alone and in combination with cancer therapy in normal tissues.

Rationale for cannabinoid agonist choice
THC was shown to induce CB1 mediated autophagic cell death in glioma cells (Salazar
et al 2009), making it an appropriate candidate to be evaluated in combination with ADR and
radiation, but wide ranging differences among cannabinoids in both structure and function within
the endocannabinoid system provide a spectrum of tools for these studies. Structurally, the
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compounds used here fall into three basic classes including a phytocannabinoid structure
similar to THC (THC, CBD, nabilone, CP55,940), the fatty acid or endogenous cannabinoid
structure (methanandamide (MAEA)) and the aminoalkylindole structure (WIN55,212-2,
pravadoline, JWH-015) (Fig 3.1A-H).
THC (Marinol) and nabilone (Cesamet) are clinically approved by the Food and Drug
Administration (FDA) as anti-emetics in chemotherapy treatment, although neither compound is
approved for palliative use in radiation therapy. THC and nabilone are currently the only FDA
approved cannabinoids in the United States. Preclinically, radiation-induced emesis in the least
shrew has been shown to be attenuated by THC, WIN55,212-2 (WIN2) and CP55,940 (Darmani
et al. 2007). Beyond palliative care, the cancer inhibiting properties of cannabinoids have only
been assessed preclinically. CBD, THC, MAEA and WIN2 have been shown to inhibit breast
cancer cell growth (Laezza et al. 2006, Legresti et al 2006, Caffarel et al 2006, Qamri et al.
2009) while CP55,940 and JWH-015 inhibit glioma cell growth (Jacobsson et al. 2001).
Pravadoline was chosen for its structure, and has not yet been demonstrated to inhibit cancer
cell growth.
In addition to their palliative or potential antitumor properties, all cannabinoids tested
have varying efficacies and affinities for CB1 and CB2, both of which are G protein coupled
receptors (GPCR). Agonist-stimulated [35S]GTPγS binding assays have shown that both WIN2
and CP55,940 are high efficacy agonists at both CB1 and CB2, while THC is a relatively low
efficacy agonists at both receptors (Sim et al. 1996, Showalter et al. 1996, Breivogel et al.
1998). JWH-015 was shown to have low affinity at CB1 receptors with a 27x greater affinity for
CB2 over CB1 (Showalter et al. 1996). Conversely MAEA, a stable analog of the rapidly
hydrolyzed endogenous cannabinoid anandamide, has CB1 selectivity with a 40x greater affinity
for CB1 over CB2 (Abadji et al. 1994, Khanolkar et al. 1996). CBD has extremely poor affinity for
CB1 (Ki=4.3 μM) and CB2 (Ki=1.2 μM) (Showalter et al. 1996), and likewise the stereoisomer of
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Figure 3.1 – Cannabinoid structures. (A) ∆9-tetrahydrocannabinol (B) Nabilone (C)
WIN55,212-2 (D) CP55,940 (E) Cannabidiol (F) Methanandamide (G) Pravadoline (H) JWH-015
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WIN2, WIN55,212-3 (WIN3), has no known agonist activity at CB1 and CB2 (Howlett et al 2002;
Savinainen et al. 2005).
A majority of the studies presented in this document utilize the synthetic cannabinoid
WIN2 due to its pharmacology (Sim et al. 1996, Showalter et al. 1996, Breivogel et al. 1998),
stereochemistry (Howlett et al 2002; Savinainen et al. 2005) and efficacy as an anti-cancer
agent (Giuliano et al. 2009; Qamri et al. 2009; Park et al. 2011; Scuderi et al. 2011; Wasik et al.
2011). As a high efficacy agonist for both cannabinoid receptors (Sim et al. 1996, Showalter et
al. 1996, Breivogel et al. 1998), the use of WIN2 in our studies prevented us from preferentially
testing one cannabinoid receptor over another. This is important, because both cannabinoid
receptors have been implicated in the growth inhibition of breast cancer cells, which will be
discussed in more detail in section 5 (Qamri et al. 2009). WIN2 also posesses an inactive
enantiomer (WIN3) that allows for the characterization of stereospecific action for differentiation
between receptor/target mediated toxicities and non-specific toxicities (Howlett et al 2002;
Savinainen et al. 2005). Finally previous reports showed that WIN2 inhibited the growth of
various types of cancer cells preclinically, including breast, hepatic, lymphoma, melanoma and
gastric cancer models (Giuliano et al. 2009; Qamri et al. 2009; Park et al. 2011; Scuderi et al.
2011; Wasik et al. 2011).

*statistical values reported in figure legends

Abbreviations

CB1-cannabinoid receptor 1; CB2-cannabinoid receptor 2; WIN2-WIN55,212-2; WIN3WIN55,212-3; IR-ionizing radiation; ADR-adriamycin; THC-∆9-tetrahydrocannabinol; CBDcannabidiol; Gy-gray (radiation dose unit); TNBC-triple negative breast cancer
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Results

Section 3.1 - WIN55, 212-2 stereoselectively inhibits breast cancer growth.

Figures 3.2-3.5 present dose-response curves for WIN2 in three breast cancer cell lines
(MCF-7, MDA-MB231 and 4T1), and one non-cancerous breast epithelial cell line (MCF-10A).
WIN3, the inactive enantiomer of WIN2, was used to assess stereoselectivity. Doses tested
include 3.75, 7.5, 15, 30 and 60 μM1. Cell density was quantified using the crystal violet assay
at 96 h. The 96 h timepoint was chosen because MCF-7 cells show significant growth arrest and
autophagic induction with both ADR and radiation treatment by this time point (Jones et al.
2005, Bristol et al. 2012, Goehe et al. 2012). WIN2 dose-dependently inhibited growth of all four
cell lines tested when compared to vehicle treatment. ED50 values for WIN2 were 11.96+1.65
μM in MCF-7 cells, 17.92+3.38 μM in MDA-MB231 cells, and 18.24+3.00 μM in 4T1 cells. In
MCF-10A cells, WIN2 achieved a maximum growth inhibition of 36% at 30 μM, preventing
calculation of the ED50. Significant differences were also found between WIN2 and WIN3 in
each cell line confirming that WIN2 mediated growth inhibition is stereospecific in nature.

Section 3.2 - WIN55, 212-2 fails to augment adriamycin induced growth inhibition

Based on studies from Goehe et al. (2012) and Salazar et al. (2009) discussed above,
ADR (100 nM, 300 nM and 1000 nM) was evaluated in combination with WIN2 (6, 12 and 18
μM) in MCF-7 cells (Fig 3.6). Trypan blue exclusion assessed viable cell number at 96 h after
treatment. Statistical analysis showed WIN2 did not significantly augment the antiproliferative
actions of ADR, even though both individual treatments dose-dependently inhibited
1

3.75 μM was not used in MCF-10A cells
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Figure 3.2 – WIN2 stereoselectively and dose-dependently inhibits the growth of MCF-7
breast cancer cells. Growth inhibition by WIN2 and WIN3 was assessed at 96 h post-treatment
by the crystal violet assay in MCF-7 cells. Data presented reflect the means of 5 individual
experiments + se; *p<0.05 WIN2 vs. WIN3 within concentration; Blackened symbols p<0.05
compared to vehicle.
Statistics
Two way repeated measures ANOVA : Drug-dose interacton (F4,15=7.5, p=0.0016)
Individual comparisons : Vehicle-WIN2 15-60 μM (p<0.0025). WIN2-WIN3 15-60 μM
(p<0.05)
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Figure 3.3 – WIN2 stereoselectively and dose-dependently inhibits the growth of MDAMB231 breast cancer cells. Growth inhibition by WIN2 and WIN3 was assessed at 96 h posttreatment by the crystal violet assay in MDA-MB231 cells. Data presented reflect the means of
5 individual experiments + se; *p<0.05 WIN2 vs. WIN3 within concentration; Blackened symbols
p<0.05 compared to vehicle.
Statistics
Two way repeated measures ANOVA : Drug-dose interacton (F4,15=7.8, p<0.0013)
Individual comparisons : Vehicle-WIN2 30-60 μM (p<0.0001). WIN2-WIN3 30-60 μM
(p<0.02)
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Figure 3.4 – WIN2 stereoselectively and dose-dependently inhibits the growth of 4T1
breast cancer cells. Growth inhibition by WIN2 and WIN3 was assessed at 96 h post-treatment
by the crystal violet assay in 4T1 cells. Data presented reflect the means of 5 individual
experiments + se; *p<0.05 WIN2 vs. WIN3 within concentration; Blackened symbols p<0.05
compared to vehicle.
Statistics
Two way repeated measures ANOVA : Drug-dose interacton (F4,15=12.8, p<0.0001)
Individual comparisons : Vehicle-WIN2 30-60 μM (p<0.0025). Vehicle-WIN3 30-60 μM
(p<0.02). WIN2-WIN3 30-60 μM (p<0.02)
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Figure 3.5 – WIN2 stereoselectively and dose-dependently inhibits the growth of nontransformed MCF-10A breast epithelial cells. Growth inhibition by WIN2 and WIN3 was
assessed at 96 h post-treatment by the crystal violet assay in MCF-10A cells. Data presented
reflect the means of 4 individual experiments + se; *p<0.05 WIN2 vs. WIN3 within concentration;
Blackened symbols p<0.05 compared to vehicle.
Statistics
Two way repeated measures ANOVA : Drug-dose interacton (F4,15=9.8, p=0.0004)
Individual comparisons : Vehicle-WIN2 30-60 μM (p<0.025). Vehicle-WIN3 60 μM
(p<0.02). WIN2-WIN3 30-60 μM (p<0.05)
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MCF-7 cell growth alone. WIN2 treatment also failed to antagonize ADR effects demonstrating a
complete lack of interaction between the treatments.

Section 3.3 - WIN55, 212-2 stereoselectively enhances antiproliferative effects of ionizing
radiation in MCF-7 cells

In addition to a cannabinoid/ADR combination it was also hypothesized that
cannabinoids would augment the antiproliferative effects of radiation (Salazar et al. 2009; Bristol
et al. 2012). The combination of WIN2 (6, 12 and 18 μM) and ionizing radiation (1, 2 and 4 Gy)
was assessed in MCF-7 cells using trypan blue exclusion at 96 h to measure cell viability (Fig
3.7A). Data analysis indicated that 12 and 18 μM WIN2 significantly augmented the
antiproliferative effects of radiation at 2 and 4 Gy. No interactions (augmentation or antagonism)
were found between the lower doses used of either treatment.
WIN3 was then used to assess stereoselectivity of the WIN2/IR interaction (Fig 3.7B).
MCF-7 cells were treated with either vehicle, WIN2 (12 μM) or WIN3 (12 μM). Drug treatments
were given alone or in combination with 2 Gy radiation, which is a ~50% effective dose at 96 h
based on results from Figure 3.7A. The combination of WIN2 and IR again elicited a significant
augmentation, but WIN3 had no effect on growth either alone or in combination with IR.
Together these studies show that WIN2 stereoselectively enhances the antiproliferative actions
of radiation in MCF-7 cells.

Section 3.4 - MCF-10a cells require higher doses of WIN55,212-2 to augment the
antiproliferative effects of radiation
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Figure 3.6 – WIN2 fails to augment ADR induced antiproliferative effects. MCF-7 cells were
exposed to treatments of WIN2 (6, 12 and 18 μM) and ADR (100, 300 and 1000nM). ADR
treatments lasted 2 h. WIN2 treatments lasted 24 h. Cells were analyzed at 96 h using trypan
blue exclusion. Data presented reflect the means of 3 individual experiments + se; no significant
interactions were found.
Statistics
Two way repeated measures ANOVA: WIN2-ADR interaction (F9,24=36.6, p<0.0001)
Individual comparisons for augmentation: no significant effects found (criteria described
in methods)
Individual comparisons for ADR to vehicle: (100 nM p=0.0064; 300 nM p=0.0004; 1000
nM p<0.0001).
Individual comparisons for WIN2 to vehicle: (6 μM p=0.1359; 12 μM p=0.0428; 18 μM
p=0.0012)
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Figure 3.7 – WIN2 stereoselectively enhances the antiproliferative effect of ionizing
radiation in MCF-7 cells. (A) Combination of WIN2 and radiation was evaluated. MCF-7 cells
were exposed to treatments of WIN2 (6, 12 and 18 μM) and IR (1, 2 or 4 Gy). (B)
Stereoselectivity of the WIN2 + IR interaction was tested using WIN3. Treatments included
WIN2 (12 μM), WIN3 (12 μM) or radiation (2 Gy). Drug treatments lasted 24 h. Cells were
analyzed at 96 h using trypan blue exclusion. Data presented reflect the means of 3-4 individual
experiments +se; (A) *=p<0.025 compared to WIN2 alone and IR alone; (B) *=p<0.05 vs vehicle
and **=p<0.025 vs WIN2 alone and IR alone.
Statistics
(A) Two way repeated measures ANOVA : WIN2-IR interaction (F12,32=31.1, p<0.0001)
(A) Individual comparisons for augmentation: 12 μM + 2 Gy (vs WIN2 p=0.0091; vs IR
p=0.0070), 12 μM + 4 Gy (vs WIN2 p=0.0020; vs IR p=0.0175), 18 μM + 2 Gy (vs WIN2
p=0.0083; vs IR p=0.0021) and 18 μM + 4 Gy (vs WIN2 p=0.0008; vs IR p=0.0020).
(B) Two way repeated measures ANOVA: (F2,12=12.8, p=0.0011)
(B) Individual comparisons with WIN2: Vehicle-WIN2 (p=0.0011). Vehicle-IR (p<0.0001).
WIN2-WIN2 + IR (p=0.0024). IR-WIN2 + IR (p=0.0013).
(B) Individual comparisons with WIN3: Vehicle-WIN3 and WIN3-WIN3 + IR comparisons
showed no significant differences
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The effect of the WIN2/IR combination was also evaluated in MCF-10A cells, an in vitro
model of normal breast epithelial tissue, to assess the selectivity of the WIN2/IR combination for
cancer cells. MCF-10A cells were treated as in Figure 3.7B before cell viability was assessed at
96 h using trypan blue exclusion (Fig 3.8A). Radiation significantly inhibited MCF-10A growth
but WIN2 showed no capacity to do the same, nor did WIN2 show any enhancement of the
antiproliferative actions of radiation.
Higher doses of WIN2 were then tested based on the dose-response curve in Figure
3.6A, which showed growth inhibitory effects at 30 μM WIN2. Using this higher dose of WIN2,
MCF-10A cells showed significant growth inhibition for WIN2, IR and WIN2 + IR (Fig 3.8B).
Comparisons also indicated that WIN2 significantly augmented the antiproliferative effects of
radiation. This indicates that WIN2 can augment the actions of radiation in non-cancerous cells
but it appears to require higher doses than those used in cancerous cells. Lastly, WIN3 showed
no ability to inhibit MCF-10A growth or augment growth inhibition when combined with radiation
confirming that WIN2 is acting in a stereospecific manner in MCF-10A cells as it did in MCF-7
cells.

Section 3.5 – WIN55, 212-2 augments the antiproliferative effects of radiation in other
breast cancer cell lines

The combination of WIN2 and IR was evaluated in MDA-MB-231 (Fig 3.9A) and 4T1
cells (Fig 3.9B). MDA-MB-231 cells were treated with vehicle, 15 μM WIN2, 2 Gy ionizing
radiation and WIN2 + IR before being analyzed at 96 h. 4T1 cells however were analyzed at 48
h due to a faster doubling rate. Treatments for 4T1 cells included 8 Gy radiation and 30 μM
WIN2. Equivalent doses of WIN3 were used to assess stereoselectivity. Both MDA-MB231 and
4T1 cells show significant growth inhibition from treatment with WIN2 alone and IR alone. WIN2
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Figure 3.8 – Increased doses of WIN2 required to augment radiation in normal breast
epithelial cells. MCF-10a cells were exposed to vehicle, WIN2 or WIN3 either alone or with 2
Gy radiation. WIN2 and WIN3 treatments were (A) 12 μM (B) 30 μM. All experiments were
analyzed for cell viability by trypan blue exclusion 96 h after drug treatment. Data presented
reflect the means of 3 individual experiments + se; *=p<0.05 vs vehicle and **=p<0.025 vs
WIN2 alone and IR alone.
Statistics
(A) No significant interactions detected
(B) Two way repeated measures ANOVA: WIN2-IR interaction (F2,8=37.6, p<0.0001)
(B) Individual comparisons with WIN2: Vehicle-WIN2 (p=0.0041). Vehicle-IR (p=0.0077).
WIN2-WIN2 + IR (p=0.0090). IR-WIN2 + IR (p=0.0058).
(B) Individual comparisons with WIN3: Vehicle-WIN3 and WIN3-WIN3 + IR comparisons
showed no significant differences
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Figure 3.9 – Enhanced antiproliferation from WIN2 and IR occurs in other breast cancer
cell lines. Cells were exposed to vehicle, WIN2 or WIN3 either alone or with radiation (A)
MDA-MB231 (2 Gy) (B) 4T1 (8 Gy). Cells analyzed for cell viability by trypan blue exclusion: (A)
96 h and (B) 48 h (due to prohibitive growth characteristics). Data presented reflect the means
of 3-4 individual experiments + se; *=p<0.05 vs vehicle and **=p<0.025 vs WIN2 alone and IR
alone.
Statistics
(A) Two way repeated measures ANOVA: WIN2-IR interaction (F2,16=4.0, p=0.0370)
(A) Individual comparisons with WIN2: Vehicle-WIN2 (p<0.0001). Vehicle-IR (p<0.0001).
WIN2-WIN2 + IR (p=0.0123). IR-WIN2 + IR (p=0.0237).
(A) Individual comparisons with WIN3: Vehicle-WIN3 and WIN3-WIN3 + IR comparisons
showed no significant differences
(B) Two way repeated measures ANOVA: WIN2-IR interaction (F2,8=14.6, p=0.0021)
(B) Individual comparisons with WIN2: Vehicle-WIN2 (p=0.0267). Vehicle-IR (p=0.0002).
WIN2-WIN2 + IR (p=0.0090). IR-WIN2 + IR (p=0.0058).
(B) Individual comparisons with WIN3: Vehicle-WIN3 and WIN3-WIN3 + IR comparisons
showed no significant differences
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significantly augmented the antiproliferative effects of radiation in both cell lines. WIN3 failed to
inhibit cell growth or augment the effects of radiation in either cell line, which confirms that the
stereospecific augmentation of radiation-induced growth inhibition generalizes to other breast
cancer cell lines.

Section 3.6 - Augmentation of radiation by cannabinoids appears to be limited to the
aminoalkylindoles

In addition to WIN2, other structurally diverse cannabinoids were given in combination
with radiation in MCF-7 cells to screen for augmented antiproliferative effects. The following
drugs were tested because of their clinical relevance, their differences in structure and/or their
variable activity within the endocannabinoid system: THC (30, 50 and 70 μM), nabilone (10, 30
and 50 μM), CBD (10, 25 and 50 μM), CP55,940 (10, 20 or 30 μM), MAEA (10, 20 or 30 μM),
pravadoline (15, 30 and 45 μM) and JWH-015 (15, 30 and 45 μM). Trypan blue exclusion was
used to assess the number of viable cells at 96 h after treatment (Table 3.1). Statistical
analyses of antiproliferative actions showed no significant interaction when radiation was
combined with THC, nabilone, CBD, CP55,940, or MAEA. Pravadoline and JWH-015, however,
were both able to significantly augment the growth inhibitory effects of radiation at the highest
doses tested for each drug (45 μM).

Section 3.7 - Evaluations of WIN55, 212-2 and radiation interaction in a syngeneic tumor
growth model

The syngeneic model of 4T1 cells in Balb/c mice was used to test the capacity of WIN2
to augment the established antiproliferative effects of radiation on tumor growth in vivo. Tumor
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Control
Drug
Vehicle

IR –
2Gy

Low dose

Medium dose

Vehicle

IR – 2Gy

Vehicle

IR –
2Gy

High dose
Vehicle

IR – 2Gy

THC

100+0.01 57+3.93

94+2.93

55+3.92

47+4.41 33+6.02

26+7.80

21+5.77

CBD

100+0.01 60+8.04

85+7.72

59+11.26 59+4.47 45+4.77

24+7.28

16+3.95

Nabilone

100+0.01 56+4.61

88+5.41

56+5.75

66+7.56 50+5.33 32+14.88

22+8.08

CP55,940

100+0.01 70+8.12 100+1.41 77+10.58 81+4.41 59+7.13

38+7.18

37+14.72

MAEA

100+0.01 61+8.89

92+0.93

58+8.33

66+7.96 47+7.25

47+9.38

32+7.98

Pravadoline

100+0.01 53+5.67

94+1.52

43+4.95

60+5.38 37+5.64

40+5.06

25+3.85 *

JWH-015

100+0.01 53+5.67

79+6.39

45+4.04

42+7.04 31+2.61

24+2.00

17+1.25 *

Table 3.1 – Interaction of cannabinoids with radiation in MCF-7 cells. MCF-7 cells were
treated with the indicated cannabinoids either alone or in combination with 2Gy radiation and
cell viability was determined based on trypan blue exclusion at 96h. Drugs concentrations ( µM)
were as follows: THC-30, 50,70; CBD-10,25,50; Nabilone-10,30,50; CP55,940-10,20,30;
Methanandamide (MAEA)-10,20,30; Provadoline-15,30,45; JWH-015-15,30,45. All data
normalized to % of control; sample size n=3-5 experiments/study; values expressed as
mean+se; *= p<0.025 vs WIN2 alone and IR alone.
Statistics
Two way repeated measures ANOVAs and individual comparisons reported no
significant interactions present for THC, CBD, nabilone, CP55,940 or MAEA
Two way repeated measures ANOVA: Pravadoline-IR interaction (F3,8=29.2, p=0.0001).
JWH-015-IR interaction (F3,8=38.4, p<0.0001)
Individual comparisons revealed no significant augmentation with the 15 and 30 µM
treatments of pravadoline and JWH-015 in combination with IR.
Individual comparisons (45 µM pravadoline): Pravadoline-Pravadoline + IR (p=0.0047).
IR-Pravadoline + IR (p=0.0028)
Individual comparisons (45 µM JWH-015): JWH-JWH + IR (p=0.0103). IR-JWH + IR
(p=0.0101).
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volume was monitored using calipers, and body weight was tracked for each mouse to screen
for general toxicity. 48 h after tumor implantation drug treatments were initiated including vehicle
(1:1:18 of ethanol:emulphor:saline), WIN2 (1, 5 and 10 mg/kg) and ADR (5 mg/kg) as a positive
control for growth inhibition (Fig 3.10A). This study was conducted with the assistance of Dr.
Qing Tao. By day 16, comparisons showed that WIN2 dose-dependently suppressed tumor
growth, but significant growth inhibition was detected as early at day 11 when compared to
vehicle. ADR showed the greatest suppression of tumor growth. Body weight measurements
are presented in Figure 3.10B. Significant changes in bodyweight were detected as early as day
7 but by day 16 WIN2 (10 mg/kg) and ADR were the only treatments to significantly increase
and decrease bodyweight, respectively. On day 16 the maximum increase in body weight by
WIN2 was 8%, and ADR had a maximum suppression of body weight at 16%.
The WIN2/IR combination was further evaluated in the 4T1-Balb/c syngeneic model by
treating subjects with vehicle, WIN2 (5 mg/kg), radiation (10 Gy) or WIN2 plus radiation. WIN3
(5 mg/kg) was also administered to evaluate stereoselectivity (Fig 3.11A). As described
previously, body weight was tracked and tumor volume was quantified using caliper
measurements. Statistical comparisons revealed no significant interactions between any
treatments at any time points in the study. Radiation significantly suppressed tumor growth at
day 15 and 17, whether given alone or in combination with WIN2/WIN3. WIN2 alone showed no
ability to significantly suppress tumor growth at any time point, which was in stark contrast to
both the multiple in vitro studies presented above and the in vivo WIN2 dose-response
presented in Figure 3.10A. Also in contrast to the in vitro studies presented above, WIN3
significantly stimulated tumor growth at days 15 and 17. These results clearly indicate that
WIN2, at the dose tested, does not augment the antiproliferative effects of radiation in vivo, but
this finding is likely confounded by the fact that WIN2 did not inhibit tumor growth in this study
(Fig 3.11A), as it did in the dose-response study presented above (Fig 3.10A). Body weight
67

was also analyzed but at no time point was any comparison found to be significantly different
from vehicle (Fig 3.11B).
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Figure 3.10 – Evaluation of WIN2 dose-dependent effects on in vivo tumor burden and
weight change. Balb/c mice were injected with 50,000 4T1 cells and measured for (A) tumor
volume and (B) body weight changes. Mice were treated with vehicle, WIN2 (1, 5 or 10 mg/kg)
or ADR (5 mg/kg) and tracked for 16 days. Mean+se; n=8 per treatment; blackened symbols
p<0.05 compared to vehicle within time points.
Statistics
(A) One way ANOVAs: day 11 (p=0.0217), day 14 (p=0.0004) and day 16 (p<0.0001)
(A) Dunnett’s post hoc comparison to vehicle: 1 mg/kg (days 11 and 16 significant). 5
mg/kg (days 11, 14 and 16 significant). 10 mg/kg (days 11, 14 and 16 significant). ADR (days 14
and 16 significant).
(B) One way ANOVAs: day 7 (p=0.0235), 9 (p=0.0240), 11 (p=0.0324), 14 (p<0.0001)
and 16 (p<0.0001).
(B) Dunnett’s post hoc comparison to vehicle: 5 mg/kg (days 7 and 9). 10 mg/kg (days 7,
9, 14 and 16). ADR (days 14 and 16).
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Figure 3.11 – Evaluation of WIN2 and WIN3 alone and with radiation on in vivo tumor
burden and weight change. Balb/c mice were injected with 50,000 4T1 cells and measured
for (A) tumor volume and (B) body weight changes. (A and B) Mice were treated with vehicle,
WIN2 (5 mg/kg) and WIN3 (5 mg/kg) either alone or in combination with 2 Gy ionizing radiation,
and tracked for 17 days. Mean+se; n=8 per treatment; blackened symbols p<0.05 compared to
vehicle within time points.
Statistics
(A) Two way ANOVAs: Drug-IR interaction (none). Drug treatment main effect (day 15p=0.0122; day 17-p=0.0028). IR treatment main effect (day 10-p=0.0215; day 13-p=0.0011; day
15-p<0.0001; day 17-p<0.0001)
(A) Individual comparisons: Vehicle-WIN2 (no significant effects). Vehicle-WIN3 (day 15p=0.0054; day 17-p=0.0091). Vehicle-IR (day 15-p=0.0126; days 17-p=0.0006)>
(B) Two way ANOVAs reported not significant effects on any days.
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Discussion

WIN2 showed no interaction (positive or negative) with ADR induced antiproliferative
actions

Both ADR and radiation treatment induce autophagy and senescent growth arrest in
MCF-7 cells (Jones et al. 2005, Bristol et al. 2012, Goehe et al. 2012), but WIN2 demonstrated
no augmentation or antagonism with ADR in MCF-7 cells. Meanwhile, WIN2 significantly
augmented the antiproliferative effects of radiation in MCF-7 cells. This difference, while
unexpected, is not necessarily surprising. When autophagy is blocked in radiation treatment
there is a shift from senescence to apoptosis (Bristol et al. 2012), but when autophagy is
blocked in ADR treatment there is a delay in senescence initiation without a significant
enhancement of antiproliferative effects of ADR (Goehe et al. 2012). Bristol et al. and Goehe et
al.’s studies clearly indicate that senescence functions differently depending on how it is
induced, and this difference means it cannot be assumed that WIN2 will interact with radiation
and ADR in the same way.

WIN2 dose-dependently inhibits breast tumor growth and augments the antiproliferative
actions of radiation stereoselectively

WIN2 dose-dependently inhibited the growth of MCF-7, MDA-MB231 and 4T1 cells, and
WIN3, the inactive enantiomer of WIN2, confirmed that in all three breast cancer cell lines this
dose-dependent growth inhibition was also stereospecific. This allows for the conclusion that
WIN2 is eliciting its antiproliferative effects through a specific site of action, and supports the
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need to elucidate a site of action for WIN2, which will be explored in later sections of this
document.
WIN2 augmented the antiproliferative effects of radiation in MCF-7 cells at 12 and 18
μM. The lower dose of WIN2 tested (6 μM) did not significantly augment effects of radiation
which suggests a significant level of growth inhibition is required from the WIN2 treatment to
interact with radiation. This is also likely true for the reverse, because the lowest dose of IR
tested (1 Gy) was not be augmented by any of the higher doses of WIN2 treatments. As with the
dose-dependent/stereospecific effects, augmentation of radiation-induced growth inhibition by
WIN2 also generalized to MDA-MB231 and 4T1 cells, indicating that the mechanism of action
for the WIN2/IR combination is not specific to one type of breast tumor cell, MCF-7s. Multiple
doses of WIN2 and IR were not tested in the MDA-MB231 and 4T1 cells as they were in MCF-7
cells, which may suggest that augmentation could be observed at lower doses than was
necessary in MCF-7 cells.
Finally, WIN3 was used to demonstrate that the augmentation of radiation by WIN2 acts
in a stereospecific manner. Dose-response experiments with WIN2 and WIN3 provide clear
evidence that showed WIN2 inhibits breast cancer cell growth in a stereospecific manner, but it
cannot be concluded that this stereospecific action is relevant to the mechanism for the WIN2/IR
combination. Additional studies showed that WIN3 did not produce inhibition of cell growth and
was incapable of augmenting the antiproliferative effects of radiation in MCF-7, MDA-MB231
and 4T1 cells. As a result, it can be concluded from the combination of all these studies that
WIN2 is acting at a specific target in three breast cancer cell lines to inhibit cell growth either
alone or in an enhanced manner through its combination with radiation.
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Relevance of WIN2 and radiation combination across MDA-MB231, 4T1 and MCF-10a
cells

MDA-MB231 and 4T1 cells
The fact that WIN2 enhanced the antiproliferative effects of radiation in multiple breast
cancer cell lines in addition to MCF-7 cells offers important insight into the generalization of the
WIN2/IR combination. More importantly though, MDA-MB231 cells are a TNBC model, which is
a disease known for short lived remission and poor five year survival relative to other forms of
breast cancer. An advantage of TNBC treatment is that patients that show CDE (22%) after
initial treatment show a better prognosis with regard to 5 year survival rates when compared to
CDE patients without TNBC (11%) after initial treatment (Liedtke et al. 2008). This observation
suggests that more efficacious therapies could increase 5 year survival rates by enhancing CDE
rates after the initial intervention. As a result, WIN2 augmentation of radiation-induced growth
inhibition in MDA-MB231 cells indicates a potential to increase patient survival after TNBC
diagnosis.
Although 4T1 cells are murine derived and MCF-7 cells are human (Aslakson et al.
1992), both cell line show enhancement of radiation-induced growth inhibition by WIN2. Testing
was primarily done in these cells to establish the model for future testing in whole animal
syngeneic tumor growth. However, the ability of the WIN2/IR interaction to span not only
species (human and mouse) but also spontaneous (MCF-7) versus carcinogen-induced (4T1)
breast cancer should not be overlooked (Aslakson et al. 1992). One of the dangers of breast
cancer is that it can evolve, in essense becoming more diverse than the original tumor, and this
diversity can increase the likelyhood of drug resistance, recurrance and death. The ability of
WIN2 to effect such different tumor types, MCF-7 versus 4T1, suggests that it can also span the
diversity that develops inside the patient, and potentially enhance patient outcomes.
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In addition to the above mentioned factors, both MDA-MB231 and 4T1 cells have a p53
status different than MCF-7 cells. p53 mutation correlates with poor patient prognosis because
of pro-cancer effects on growth, tumorigenicity, DNA repair, cell death, angiogenesis and
metastasis (Lacroix et al 2006, Walerych et al 2012). Importantly, the sensitivity of mutant p53
MDA-MB231 and p53 null 4T1 cells to the WIN2 augmentation of radiation clearly shows that
p53 status is not relevant (Lacroix et al 2006, Yerlikaya et al. 2012). The common nature of p53
mutations in 31% of all cancers and ~23% of breast cancers further highlight the importance of
this observation.

MCF-10a
MCF-10a cells are an immortalized breast epithelial cell line that demonstrated WIN2
dose-dependently inhibited their growth and augmenting the antiproliferative actions of
radiation, like was revealed in MCF-7 cells (Soule et al. 1990). Uniquely though, MCF-10A cells
required higher doses of WIN2 to inhibit MCF-10A cell growth compared to MCF-7 cells, 30
versus 12 μM, respectively. The need for higher doses in the MCF-10A cells extended to the
augmentation of radiation as well, and this decreased sensitivity of MCF-10A cells to the
antiproliferative effects of WIN2 alone or in combination with radiation indicates a potential
selectivity for tumor cells. Shrivastava et al. (2011) had previously demonstrated that MDAMB231 cells were more sensitive to the cannabinoid CBD than MCF-10A cells supporting the
findings presented in this document regarding cannabinoid selectivity for tumor cells over noncancerous MCF-10A cells. This selectivity supports the hypothesis that WIN2 has a therapeutic
window for treatment that would be beneficial to patient outcomes.
However, as exciting as these findings could be for the patient, the MCF-10A studies are
not without their limitations. First, the MCF-10A cells in culture are a proliferating population and
breast epithelial cells are largely non-proliferative. Later studies will show that WIN2 elicits a
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growth inhibitory mechanism in MCF-7 cells versus cell death, and a growth inhibitory
mechanism is likely to have a diminished if not non-existent antiproliferative effect in a nonproliferating population. This may suggest further analysis of toxicities would show an even
greater therapeutic window for WIN2 treatments. Second, breast epithelial cells are not the only
cell types found within the path of ionizing radiation in the breast. Fibroblasts are a common cell
type that can be analyzed, either as mouse embryonic fibroblasts or an immortalized fibroblast
cell line, to assess WIN2 augmentation of IR toxicities. Finally, unlike radiation, WIN2 is a drug
that will likely spread systemically via the circulation and it may have an effect on tissues
outside of the breast, especially those that are rapidly dividing like that gastrointestinal epithelial
cells or bone marrow. Testing for toxicities in these cell types with WIN2 treatment might prove
pertinent.

Aminoalkylindole cannabinoids are more efficacious at augmenting the antiproliferative
effects of radiation than other cannabinoids tested

THC, CBD, nabilone, CP55,940 and MAEA all show lack of interaction with radiation in
MCF-7 cells, while JWH-015 and pravadoline augmented the effects of radiation at the high
doses tested similar to WIN2. The clinical relevance of THC (Marinol) and nabilone (Cesamet)
make a lack of antagonism worth noting however. Patients are given palliative treatment with
Marinol and Cesamet for chemotherapy (Russo 2008), and chemotherapy is often given in
combination with radiation therapy (Kaviani et al. 2013; Joeger et al. 2013; Yang et al. 2013).
The lack of antagonism by THC and nabilone in the studies presented above offer preclinical
evidence that these palliative treatments will not interfere with radiation therapy should they be
in the patient’s system during treatment.
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Comparing structural differences of the cannabinoids that successfully augmented the
antiproliferative effects of radiation (WIN2, JWH-015, pravadoline) versus those that did not
(THC, CBD, nabilone, CP55,940, MAEA) clearly reveals that the aminoalkylindoles had a
greater capacity to augment effects of radiation based on the compounds tested in these
studies. The structures of each drug are presented in Figure 3.1. While it remains unclear at this
time what aspect of the aminoalkylindole structure allows for the capacity to augment radiationinduced growth inhibition, future studies investigating structure-activity relationships could
elucidate this structural selectivity. Augmentation of radiation by JWH-015 also poses an
additional benefit, in that JWH-015 is a CB2 specific agonist (Showalter et al. 1996). This is
advantageous as CB2 agonists are absent of the cannabimimetic effects that have blunted the
potential for clinical development of WIN2 and other drugs like it (Howlett et al. 2002; Pertwee et
al. 2010). Development or screening of additional aminoalkylindole analogs could provide
compounds with a greater efficacy for augmentation of radiation effects without the unwanted
psychoactive properties.

The ability of WIN2 to augment radiation in vivo cannot be determined based on current
studies

WIN2 and IR were given in combination to test the ability of WIN2 to augment radiationinduced growth inhibition in vivo. The in vivo model used for this was the 4T1-Balb/c syngeneic
model, but the results of these studies are inconclusive regarding the effects of the WIN2/IR
combination in vivo. This is due to the fact that the dose of WIN2 tested did not inhibit tumor
growth and in vitro studies using MCF-7 cells showed that effective doses of WIN2 and/or IR
were required for augmentation to occur. The in vivo combination studies could have been
repeated using higher doses of WIN2, but this approach would conflict with observations from
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the dose response study. 1, 5 and 10 mg/kg WIN2 dose-dependently inhibited tumor growth in
the same 4T1-Balb/c syngeneic tumor growth model. Even if 5 mg/kg hypothetically showed an
unusually high level of growth inhibition in the dose-response study, 1 mg/kg WIN2 was also
found to significantly inhibit tumor growth, which suggests that even accounting for variability
between experiments, 5 mg/kg WIN2 should have inhibited tumor growth. Additionally,
repeating the experiment until 5 mg/kg WIN2 demonstrated tumor growth inhibition was not
considered because of obvious ethical considerations.It is unclear why 5 mg/kg WIN2 inhibited
tumor growth in the dose-response study but failed to do so in the combination study, and to
date no variables have been identified that reconcile the difference between these studies.
Since the 4T1-Balb/c model has proven unreliable in my hands it seems logical that
future in vivo studies be moved to another in vivo model until the factors causing the above
described variability of the 4T1 model can be identified. Options for additional models include
estrogen pelleted immune-deficient SCID mice bearing MCF-7 tumors, or immune-deficient
SCID mice bearing MDA-MB231 cells. It does, however, remains pertinent to evaluate the in
vivo actions of the WIN2/IR combination in an immune competent model, based on the
argument described in the introduction of this section, but MCF-7 and MDA-MB231 cells are
human derived and cannot be transplanted in vivo without immune complications. Therefore
future studies would require the in vitro evaluation of the WIN2/IR combination in a new murine
derived tumor model.

Summary

The studies in this chapter have effectively demonstrated the proof of principle for WIN2
to augment the antiproliferative actions of radiation in vitro, using multiple breast cancer cell
lines. This augmentation was shown to be stereospecific in nature, did not translate to other
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cancer therapeutic treatments tested, demonstrated potential selectivity between cancer and
non-cancerous cells and might be unique to the aminoalkylindole class of cannabinoids. The in
vivo studies using the 4T1-Balb/c model were the first attempt to demonstrate translatability of
this WIN2/IR combination, but the results were uninterpretable and the model was proven
unreliable. Future studies could use a variety of in vivo models, but regardless of the in vivo
model chosen it is important that these studies move beyond the in vitro setting, because
without demonstrating the WIN2/IR combination in a whole animal model, the combination of
cannabinoids and radiation can never be considered a viable therapeutic strategy.
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Section 4
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Evaluation of antiproliferative mechanisms governing WIN2/IR interaction

The antiproliferative effects of radiation in the treatment of cancer are caused by DNA
damage which is primarily driven by radiolysis of water leading to the formation of reactive
oxygen species (ROS) (Narayanan et al. 1997). This ROS formation is responsible for DNA
damage expressed primarily as single and double strand breaks in DNA (Driessens et al. 2009).
Radiation-induced DNA damage causes MDA-MB231 breast tumor cells to undergo apoptotic
cell death demonstrated by TUNEL staining, but MCF-7 cells undergo senescent growth arrest
shown by pH 6.0 dependent β-galactosidase staining (Jones et al. 2005). Artificial expression of
caspase-3 in the caspase-3 deficient MCF-7 cells can induce a modest apoptotic response to
radiation treatment; a robust apoptotic response requires simultaneous administration of the
ATM inhibitor, caffeine and re-expression of caspase-3 in MCF-7 cells (Essmann et al. 2004).
Work from Essmann et al. and Jones et al. provide evidence that the antiproliferative
mechanisms of radiation are contextually dependent on the system.
Cannabinoids also have multiple antiproliferative mechanisms depending on the
cannabinoid agonist used and the cancer cell type investigated. These mechanisms include
autophagy (Salazar et al. 2009; Shrivastava et al. 2011, Donadelli et al. 2011, Dando et al.
2013), cell death (Giullino et al. 2009; Qamri et al. 2009; Caffarel et al. 2010) and growth arrest
(Galanti et al. 2008; Park et al. 2011). However, DNA damage and senescent growth arrest
have not yet been associated with cannabinoid treatment in preclinical cancer models.
∆9-tetrahydrocannabinol (THC) treatment-induced autophagy in U87-MG glioblastoma
cells based on GFP-LC3 puncta formation and electron microscopic autophagosome imaging,
and knockdown of the autophagy genes ATG1 and ATG5 resulted in increased viable cell
number (Salazar et al. 2009). Other studies have linked cannabinoid-induced autophagy to a
ROS mediated mechanism (Shrivastava et al. 2011, Donadelli et al. 2011, Dando et al. 2013).
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In MDA-MB231 cells, cannabidiol (CBD) induced autophagy based on LC3 cleavage and
electron microscopic autophagosome imaging. LC3 cleavage was antagonized by the
autophagy inhibitor bafilomycin and the ROS scavenger α-tocopherol (Shrivastava et al. 2011).
In Panc1 cells the ROS scavenger N-acetyl-cysteine was shown to inhibit autophagy induction
under synthetic cannabinoid treatment, GW405833 and arachidonoyl cyclopropamide.
Autophagy was quantified by LC3 cleavage, acridine orange staining and flow cytometric
quantification of autophagolysosomal staining by MDC (Donadelli et al. 2011, Dando et al.
2013).
Shrivastava et al. (2011) and Salazar et al. (2009) showed that CBD and THC,
respectively, induced autophagic effects that were linked to the induction of apoptosis, and this
finding that cannabinoids induced apoptosis is supported by numerous studies. ErbB2 positive
tumors produced by MMTV-neu transgenic animals treated with THC and the synthetic
cannabinoid JWH-133 express higher levels of cleaved caspase-3 when compared to vehicle
(Caffarel et al. 2010). WIN55, 212-2 (WIN2) increased apoptotic markers in HepG2 cells with
concomitant increases in the sub-G1 population, annexin V/propidium iodide (PI) positive
staining and cleaved caspase 3 expression (Giullino et al. 2009). Qamri et al. (2009) showed
that WIN2 and JWH-133 induce apoptosis in MDA-MB231 cells based on an increased sub-G1
population, TUNEL staining and imaging of apoptotic nuclei.
In addition to cell death, another common antiproliferative mechanism is growth
inhibition. Park et al. (2011) showed that WIN2 treatment induced growth arrest in gastric
cancer cells through downregulation of E2F1 and several cyclins and cyclin dependent kinases.
Park et al. furthermore linked WIN2 growth arrest to inhibition of the survival protein pAKT. Park
et al.’s observations support an earlier study by Galanti et al. (2008) where THC caused growth
arrest via down regulation of E2F1 and cyclin A in both U251-MG and U87-MG human
glioblastoma cell lines. Galanti et al.’s findings with THC in U87-MG cells are contradictory to
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those from Salazar et al. (2009) in which THC induced autophagic cell death in U87-MG cells,
but this could be explained by Salazar’s use of media containing low serum, which tends to be
permissive for autophagy, and Galanti’s opposite use of media containing normal serum
concentrations.
A primary goal of these studies was to assess the antiproliferative mechanism(s) for
radiation and WIN2 alone and in combination. MCF-7 cells treated with the WIN2/IR
combination were tested for ROS mediated antiproliferative actions, cell death (including
apoptosis, necrosis, mitotic catastrophe and autophagy), changes in the DNA damage response
and growth arrest (both classical and senescent).

*statistical values reported in figure legends

Abbreviations
ROS-reactive

oxygen

species;

THC-∆9-tetrahydrocannabinol;

WIN2-WIN55,212-2;

CQ-

chloroquine; PI-propidium iodide; ADR-adriamycin; NAC- N-actyl-cysteine; GSH-glutathione; IRionizing radiation; Gy-gray (radiation dose unit); AO-acridine orange;
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Results

Section 4.1 - Autophagy is induced in MCF-7 cells but does not appear to be relevant to
WIN2 growth inhibitory mechanisms

In a previous chapter, it was hypothesized that WIN2 augmentation of the
antiproliferative actions of radiation would be mediated by an autophagic mechanism based on
evidence from Salazar et al. 2009 and Bristol et al. 2012. To qualitatively establish the presence
of autophagy, MCF-7 cells were treated with vehicle, 12 μM WIN2, 2 Gy radiation or the
combination of WIN2 + IR. At 96 h, the treated cells were stained with acridine orange (AO) and
imaged. The presence of increased numbers of orange vesicles compared to vehicle treatment
confirmed the promotion of autophagy in cells exposed to WIN2, IR and WIN2 + IR (Fig 4.1A).
To evaluate the potential involvement of autophagy in the antiproliferative effects of the
WIN2/IR combination, cells were treated with the autophagic inhibitor chloroquine (CQ) at 5 μM
in combination with the WIN2/IR combination before quantification of cell viability using trypan
blue exclusion. At 96 h, CQ had no effect on viable cell number in cells treated with the vehicle,
WIN2, IR or WIN2 + IR (Fig 4.1B). Acridine orange staining was used to qualitatively confirm
that the 5 μM CQ treatment was properly inhibiting autophagy. Markers for blockade of
autophagy in AO staining include increased vesicle number (blocked degradation) and a yellow
color as opposed to orange (incomplete acidification). MCF-7 cells were treated with vehicle,
adriamycin (ADR; 1 μM) or ADR + CQ before being stained with AO and imaged (Fig 4.1C).
ADR induced autophagy compared to vehicle, shown by an increase in orange vesicles. CQ
blocked autophagy compared to ADR, shown by an increase in yellow vesicle number. Similar
results with ADR and CQ were previously demonstrated in Goehe et al. 2012. These combined
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Figure 4.1 – Autophagy is induced by radiation and WIN2 but not involved in growth
inhibition. Acridine orange staining was used to image autophagic vesicles in MCF-7 cells
treated with vehicle, 12 μM WIN2, 2 Gy IR or WIN2 + IR (A). Cell viability was quantified using
trypan blue exclusion in MCF-7 cells treated as in (A) with a co-treatment of either vehicle or 5
μM chloroquine (B). Acridine orange staining was used to image autophagic vesicles in MCF-7
cells treated with vehicle, 1 μM ADR or ADR + 5 μM chloroquine (C). In (B) data were
normalized to % of control and presented as the means of 3 individual experiments + se; no
significant differences detected.
Statistics
(B) Two way repeated measures ANOVA: Chloroqine-combo interaction (p=0.8842)
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results indicate that while autophagy is clearly induced, autophagy does not appear to be
relevant to the antiproliferative actions of WIN2, IR or WIN2 + IR.

Section 4.2 - ROS do not mediate antiproliferative effects of the WIN2/IR combination

ROS have been shown to mediate cannabinoid based growth inhibition (Shrivastava et
al. 2011, Donadelli et al. 2011, Dando et al. 2013, Driessens et al. 2009). To assess the
involvement of ROS in the antiproliferative actions of the WIN2/IR combination, MCF-7 cells
were treated with the antioxidants N-actyl-cysteine (NAC; 1 mg/ml) and glutathione (GSH; 0.5
mg/ml). NAC and GSH treatment lasted 48 h beginning 24 h before the WIN2/IR treatment (Fig
4.2A-B). 96 h after WIN2/IR were administered to MCF-7 cells neither NAC nor GSH
demonstrated any ability to decrease viable cell number in MCF-7 cells. H2O2 (9.79 μM) was
used as a positive control for ROS induced growth inhibition, and both NAC and GSH
significantly protected MCF-7 cells from H2O2 insult at 96 h. These data demonstrate that ROS
signaling does not mediate the antiproliferative actions of the WIN2/IR combination.

Section 4.3 - The WIN2/IR combination does not induce cell death in MCF-7 breast tumor
cells

As indicated in the introduction, previous studies have documented the capacity of
cannabinoids to induce apoptosis (Shrivastava et al. 2011, Salazar et al. 2009, Caffarel et al.
2010, Giullino et al. 2009, Qamri et al. 2009). In order to confirm this in our system, annexin
V/PI staining was used to assess apoptosis and necrosis, respectively, at 48 h post treatment
with the WIN2/IR combination (Fig 4.3A). Flow cytometric quantification showed no change in
the percentage of healthy, apoptotic or necrotic cells treated with WIN2, IR or WIN2 + IR
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Figure 4.2 – ROS do not mediate the antiproliferative effects of the WIN2/IR combination.
MCF-7 cells were treated with vehicle, WIN2 (12 μM), IR (2 Gy), WIN2 + IR or hydrogen
peroxide (9.79 μM). Co-treatments were given of either vehicle, (A) NAC (1 mg/ml) or (B) GSH
(0.5 mg/ml). Cell viability was quantified at 96 hrs using trypan blue exclusion. Data were
normalized to % of control and presented as the means of 3 individual experiments + se;
*=p<0.05.
Statistics
(A) Two way repeated measures ANOVA: NAC-combo (p=0.1638)
(A) Positive control vs. NAC paired t-test (p=0.0043)
(B) Two way repeated measures ANOVA: GSH-combo (p=0.1507)
(B) Positive control vs. GSH paired t-test (p=0.0079)
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Figure 4.3 – Apoptosis, necrosis and mitotic catastrophe are not involved in the
antiproliferative actions of the WIN2/IR combination. MCF-7 cells were treated with vehicle,
WIN2 (12 μM), IR (2 Gy) or WIN2 + IR. Staurosporine (1 μM) and Paclitaxel (1 μM) were used
as positive controls. (A) Flow cytometry was used to quantify annexin V and PI staining at 48
hrs. (B) Dapi staining was used to assess nuclear morphology at 40x magnification. Data
normalized to % of population in (A); data presented reflect the means of 3-4 individual
experiments + se; *p<0.05 vs vehicle.
Statistics
(A) Two way repeated measures ANOVA: no significant differences for healthy, apoptotic
or necrotic cells
(A) Staurosporine paired t-test: healthy cells (p=0.0141). Apoptotic cells(p=0.0192). Necrotic
cells (p=0.0396).
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compared to vehicle. A 1 μM staurosporine treatment for 24 h was used as a positive control for
apoptosis and necrosis, and this treatment produced a significant decrease in healthy cells, with
significant increases in both apoptotic and necrotic cells.
To confirm the absence of cell death in MCF-7 cells treated with the WIN2/IR
combination, nuclear morphology was assessed at 48, 72 and 96 h using DAPI staining (Fig
4.3B). 0.5 μM of the microtubule poison, paclitaxel, was used as a positive control for apoptotic
nuclear morphology. DAPI staining was also used to screen for multinucleated cells, a marker of
mitotic catastrophe (Jonathan et al. 1999). At 48, 72 and 96 h, no evidence of cell death was
detected except in the positive control. Taken together, these results strongly argue that the
antiproliferative effects of the WIN2/IR combination are not mediated by apoptosis, necrosis or
mitotic catastrophe in MCF-7 cells.

Section 4.4 - Temporal effects of the WIN2/IR combination in breast cancer cells

The absence of evidence for a cell death mechanism, lead us to predict that growth
inhibition was likely mediating the antiproliferative actions of the WIN2/IR combination. To test
this hypothesis, trypan blue was used to assess cell viability at 24, 48, 72 and 96 h in MCF-7
cells treated with the WIN2/IR combination (Fig 4.4). WIN2, IR and WIN2 + IR were all
significantly different from vehicle at 48, 72 and 96 h, which confirmed the growth inhibition
hypothesis. Decreases in doubling times after treatment emphasize the presence of growth
inhibition. Doubling time presented in hrs (mean+se): vehicle – 27.7+2.6, WIN2 – 44.6+7.7, IR –
36.8+4.9 and WIN2 + IR – 68.3+9.8.
A cell viability time course was also evaluated in MDA-MB231 breast tumor cells exposed
to the WIN2/IR combination treatment (Fig 4.5). MDA-MB231 cells were treated with 15 μM
WIN2 and 2 Gy radiation. Statistical comparisons showed that growth inhibition was detected as
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Figure 4.4 – Temporal effects of WIN2 and IR combination in MCF-7 breast cancer cells.
MCF-7 cells were treated with vehicle, WIN2 (12 μM), IR (2 Gy) or WIN2 + IR treatments. Viable
cell number was monitored over a period of 96 h using the trypan blue exlusion assay. Data
presented reflect the means of 5 individual experiments + se. Darkened symbols = p<0.05 vs
vehicle within time points.
Statistics
24 h – No significant differences
48 h – Repeated measures ANOVA (p<0.0001) with Dunnett’s post hoc (WIN2, IR and
WIN2 + IR significant from vehicle)
72 h – Repeated measures ANOVA (p<0.0001) with Dunnett’s post hoc (WIN2, IR and
WIN2 + IR significant from vehicle)
96 h – Repeated measures ANOVA (p=0.0006) with Dunnett’s post hoc (WIN2, IR and
WIN2 + IR significant from vehicle)
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Figure 4.5 – Temporal effects of WIN2 and IR combination in MDA-MB231 breast cancer
cells. MDA-MB231 cells were treated with vehicle, WIN2 (15 μM), IR (2 Gy) or WIN2 + IR
treatments. Viable cell number was monitored over a period of 96 h using the trypan blue
exlusion assay. Data presented reflect the means of 5 individual experiments + se. Darkened
symbols = p<0.05 vs vehicle within time points.
Statistics
24 h – No significant differences
48 h – Repeated measures ANOVA (p=0.0062) with Dunnett’s post hoc (WIN2 and
WIN2 + IR significant from vehicle)
72 h – Repeated measures ANOVA (p=0.0011) with Dunnett’s post hoc (WIN2, IR and
WIN2 + IR significant from vehicle)
96 h – Repeated measures ANOVA (p<0.0001) with Dunnett’s post hoc (WIN2, IR and
WIN2 + IR significant from vehicle)
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Figure 4.6 – Temporal effects of WIN2 and IR combination in 4T1 breast cancer cells. 4T1
cells were treated with vehicle, WIN2 (30 μM), IR (8 Gy) or WIN2 + IR treatments. Viable cell
number was monitored over a period of 48 using the trypan blue exlusion assay. Data
presented reflect the means of 5 individual experiments + se. Darkened symbols = p<0.05 vs
vehicle within time points.
Statistics
24 h – Repeated measures ANOVA (p=0.0352) with Dunnett’s post hoc (IR and WIN2 +
IR significant from vehicle)
48 h – Repeated measures ANOVA (p<0.0001) with Dunnett’s post hoc (WIN2, IR and
WIN2 + IR significant from vehicle)
WIN2 (0-24 h) – Repeated measures ANOVA (p=0.0438) with Dunnett’s post hoc (no
treatments significantly different from time 0)
IR (0-24 h) – Repeated measures ANOVA (p=0.0051) with Dunnett’s post hoc (IR and
WIN2 + IR significantly different from time 0)
WIN2 + IR (0-24 h) – Repeated measures ANOVA (p=0.0166) with Dunnett’s post hoc
(WIN2 + IR significantly different from time 0)
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early as 48 h in the WIN2 and WIN2 + IR groups but by 72 and 96 h, all treatment groups
showed significant growth inhibition compared to vehicle. These results support those reported
using MCF-7 cells.
Different than MCF-7 or MDA-MB231 cells, 4T1 cell assessment of temporal effects
indicates evidence for cell death with the WIN2/IR combination. 4T1 cells were treated with 30
μM WIN2 and 8 Gy IR before assessment at 24 and 48 h (Fig 4.6). Antiproliferative action was
detected in the IR and WIN2 + IR group at 24 h and all treatment groups at 48 h when
compared to vehicle. Interestingly, significant decreases in viable cell number compared to time
0 showed evidence for cell death in the IR treatment at 24 h and the WIN2 + IR treatment at 24
and 48 h. This suggests that WIN2 and IR may be interacting via a cytotoxic mechanism in 4T1
cells.

Section 4.5 - Radiation but not WIN2 induces DNA damage in breast cancer cells

Antiproliferative effects of IR have been linked to the induction of DNA damage
(Narayanan et al. 1997). γH2AX is a protein recruited to DNA repair complexes that is rapidly
degraded after the completion of DNA repair. As a result, it is used to monitor the DNA repair
response process (Rogakou et al. 1999). Changes in γH2AX expression after radiation
treatment were used to assess the potential influence of the WIN2/IR combination on DNA
damage induction (1 h) and repair (24 h) in MCF-7, MDA-MB-231 and 4T1 cells (Fig 4.7-4.9).
In MCF-7 cells, radiation significantly increased γH2AX expression at 1 h, while WIN2
alone had no effect on γH2AX. Interaction comparison indicates that WIN2 had no effect on the
level of γH2AX induction by IR at 1 h, which indicates WIN2 had no effect on DNA damage
induction either alone or in combination with IR. By 96 h γH2AX levels in all treatments had
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Figure 4.7 – DNA damage and repair in breast cancer cells treated with WIN2 and
radiation. MCF-7 figure 4.4. γH2AX formation analyzed by flow cytometry at 1 h and 24 h after
drug treatment. Data were normalized to percent of control; data presented reflect the means of
3-5 individual experiments + se; *p<0.05 vs vehicle.
Statistics
1 h – Two way repeated measures ANOVA: WIN2-IR interaction (p=0.5521). IR
treatment main effect (p=0.0003).
1 h – Individual comparisons: Vehicle-IR (p=0.0233). Vehicle-WIN2 + IR (p=0.0240).
24 h – Two way repeated measures ANOVA: WIN2-IR interaction (p=0.8510). IR
treatment main effect (p=0.0343).
24 h – Individual comparisons: no significant differences

93

Figure 4.8 – DNA damage and repair in breast cancer cells treated with WIN2 and
radiation. MDA-MB231 cells were treated as in figure 4.5. γH2AX formation analyzed by flow
cytometry at 1 h and 24 h after drug treatment. Data were normalized to percent of control; data
presented reflect the means of 3-5 individual experiments + se; *p<0.05 vs vehicle.
Statistics
1 h – Two way repeated measures ANOVA: WIN2-IR interaction (p=0.1189). IR
treatment main effect (p=0.0194).
1 h – Individual comparisons: Vehicle-IR (p=0. 0289). Vehicle-WIN2 + IR (p=0. 0126).
24 h – Two way repeated measures ANOVA: WIN2-IR interaction (p=0.6982). IR
treatment main effect (p=0.0160).
24 h – Individual comparisons: Vehicle-WIN2 + IR (p=0.0127)
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Figure 4.9 – DNA damage and repair in breast cancer cells treated with WIN2 and
radiation. 4T1 cells were treated as in figure 4.6. γH2AX formation analyzed by flow cytometry
at 1 h and 24 h after drug treatment. Data were normalized to percent of control; data presented
reflect the means of 3-5 individual experiments + se; *p<0.05 vs vehicle.
Statistics
1 h – Two way repeated measures ANOVA: WIN2-IR interaction (p=0.5203). IR
treatment main effect (p=0.0063).
1 h – Individual comparisons: Vehicle-IR (p=0.0138). Vehicle-WIN2 + IR (p=0.0078).
24 h – Two way repeated measures ANOVA: WIN2-IR interaction (p=0.7009). IR
treatment main effect (p=0.0313).
24 h – Individual comparisons: Vehicle-WIN2 + IR (p=0. 0396)
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returned to baseline levels relative to vehicle demonstrating that WIN2 had no effect on the
DNA repair process in MCF-7 cells.
In MDA-MB231 and 4T1 cells radiation significantly increased γH2AX expression at 1 h
and WIN2 alone had no effect. WIN2 + IR displayed no greater induction of γH2AX at 1 h than
IR alone indicating WIN2 had no effect on DNA damage induction either alone or in combination
with IR. By 96 h γH2AX levels in WIN2 alone and IR alone treatments had returned to baseline
levels, but γH2AX in the WIN2 + IR treatment remained significantly different from vehicle.
Nevertheless, statistical comparisons showed no significant interaction between the WIN2 and
IR treatments indicating no presence of augmentation. These results confirm that like in MCF-7
cells, WIN2 had no effect on the induction or repair of DNA damage in MDA-MB231 or 4T1
cells.

Section 4.6 - Radiation but not WIN2 induces senescence in MCF-7 cells

Jones et al. (2005) established that radiation treatments induced growth arrest via
senescence in MCF-7 cells. To test the induction of senescence, the β-galactosidase assay was
used to quantify cells treated with vehicle, WIN2 (12 μM), IR (2 Gy) or WIN2 + IR (Fig 4.10A-B).
At 96 h, radiation significantly induced senescence, WIN2 had no ability to induce senescence
and interaction comparisons confirm WIN2 had no significant effect on the level of radiationinduced senescence. These studies confirm previous reports that radiation inhibits growth via
senescence (Jones et al. 2005), and in the absence of senescence it can be concluded that
growth inhibition after WIN2 treatment is classical growth arrest.
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Figure 4.10 – Senescence induction by radiation ± WIN2. MCF-7 cells were treated with
vehicle, WIN2 (12μM), (2Gy) radiation or WIN2 + radiation. (A) Representative images of βgalactosidase stained cells. (B) Quantification of β-galactosidase activity 96 h after drug
treatment. Data were normalized to % of sample in (B); data presented reflect the means of 3
individual experiments + se; *p<0.05 vs vehicle.
Statistics
(B) Two way repeated measures ANOVA: WIN2-IR interaction (p=0.6618). IR treatment
main effect (F1,4=72, p=0.0011).
(B) Individual comparisons: Vehicle-IR (p=0.0382). Vehicle-WIN2 + IR (p=0.0310)
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Discussion

It was originally hypothesized that WIN2 would augment the impact of radiation in breast
tumor cells through an autophagic mechanism based on observations from Salazar et al. 2009
and Bristol et al. 2012. In the studies presented above WIN2, IR and WIN2 + IR were capable of
inducing autophagy in MCF-7 cells; however based on the inability of CQ to alter MCF-7
response to WIN2, IR or WIN2 + IR, it can be concluded that autophagy is not relevant to the
antiproliferative mechanisms for these three treatments, and furthermore autophagy is not
involved in WIN2 augmentation of radiation.
One discrepancy regarding autophagy induction in these studies and in the work of
Bristol et al. (2012) is that in Bristol et al., CQ enhanced the antiproliferative effects of radiation
in MCF-7 cells. A CQ induced enhancement of the antiproliferative effects of radiation was not
observed in the studies presented above. This might be explained by the different doses of
radiation used between the studies (1x2 Gy here; 5x2 Gy in Bristol et al.), which could lead to
different autophagic mechanisms. In fact, Bristol et al. observed that autophagy had different
mechanisms of action depending on the conditions of the system, which suggests that the
relatively low radiation dose of 2 Gy used in the current work simply may not have been
sufficient to induce the protective autophagy that was reported in Bristol et al. 2012.
Previous studies have connected the antiproliferative actions of cannabinoids to ROS
induced autophagy (Shrivastava et al. 2011, Donadelli et al. 2011, Dando et al. 2013). As
autophagy was apparently not directly relevant to the antiproliferative mechanism of the
WIN2/IR combination, and the antioxidants NAC and GSH were unable to rescue MCF-7 cells
from the antiproliferative actions of the WIN2, IR or the WIN2 + IR combination, it can be
concluded that ROS do not mediate the antiproliferative effects of WIN2, IR or WIN2 + IR. On
the other hand, it is well documented that ROS mediate the DNA damaging effects of radiation
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therapy (Driessens et al. 2009), and NAC or GSH failed to protect MCF-7 cells from radiation
might be confusing. However, this discrepancy can be explained by a report that has shown
increased GSH levels from NAC treatment were unable to protect lung tumor cells from the
antiproliferative effects of ionizing radiation (Wanamarta et al. 1998), and another study showed
that overexpressing glutathione peroxidase in MCF-7 cells protected the cells from H2O2
treatment but not radiation treatment (Liebmann et al. 1995). Based on the Wanamarta et al.
and Liebmann et al. studies, it is understandable that NAC and GSH can protect MCF-7 cells
from the antiproliferative effects of H2O2 but not from radiation.
Annexin V and PI staining as well as DAPI nuclear staining showed that WIN2, IR and
WIN2 + IR fail to induce apoptosis, necrosis and mitotic catastrophe in MCF-7 cells. The
absence of these three cell death mechanisms as well as evidence that autophagy is not
associated with the antiproliferative action of the WIN2/IR combination strongly argue that
growth inhibition and not cell death is mediating the antiproliferative actions of WIN2, IR and
WIN2 + IR. A growth inhibition hypothesis is also evident in the time course studies in MCF-7
cells treated with WIN2, IR and WIN2 + IR, as well as reports from the literature where WIN2
induced growth arrest as its primary mechanism of action (Park et al. 2011). Therefore, it
appears likely that augmentation of IR induced growth inhibition by WIN2 is expressed in at
least one of two ways, which is by the augmentation of one growth inhibitory pathway or the
activation of two parallel growth inhibitory pathways. The two primary growth inhibitory pathways
are senescence, involving the activation of a specific signalling process, or classical growth
arrest, which is a more broad suppression of mitogenic signals (Blagosklonny et al. 2003).
Previous studies have demonstrated using the β-galactosidase assay that radiation-induced
growth inhibition is expressed as senescent growth arrest in MCF-7 cells (Jones et al. 2005).
WIN2, however, failed to induce senescence or to augment the induction of senescence by
radiation in MCF-7 cells. These combined observations demonstrate that growth inhibition by
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WIN2 is mediated by classical growth arrest, either expressed as cell cycle arrest or growth
delay, and the augmentation of IR treatment by WIN2 is expressed as two parallel pathways of
growth inhibition, growth arrest and senescence.
DNA damage is believed to be responsible for the induction of senescence by radiation
in MCF-7 cells (Jones et al. 2005). Tracking the DNA damage response by monitoring the
induction and decline of γH2AX (Rogakou et al. 1999) confirmed the presence of DNA damage
by radiation in MCF-7 cells. These experiments also confirmed that WIN2 has no ability to
enhance induction of DNA damage, induce DNA damage or alter the DNA repair process. Lack
of interaction between WIN2 and IR treatment on γH2AX induction was also demonstrated in
the MDA-MB231 and 4T1 cells. The absence of interaction between WIN2 and IR in the DNA
damage response pathway supports the hypothesis that WIN2 and IR are acting via parallel
mechanisms of growth inhibition rather than by a common pathway.
The conclusion of parallel growth inhibitory pathways cannot be extended to the MDAMB231 and 4T1 cells for multiple reasons. First, MDA-MB321 cells have previously been shown
to respond to radiation therapy via an apoptotic mechanism and not senescence (Jones et al.
2005). Second, the time course viability studies for 4T1 cells shows that at 24 h radiation and
WIN2 + radiation significantly decrease viable cell number compared to the 0 h controls,
indicating cell death as opposed to growth arrest. These lines of evidence supporting radiationinduced cell death mechanisms in MDA-MB231 and 4T1 cells do, however, allow for the
conclusion that the interaction of WIN2 and IR in MDA-MB231 and 4T1 cells is different than for
MCF-7 cells. If the mechanism of growth inhibition for WIN2 in MCF-7 cells extends to MDAMB231 and 4T1, it would be logical to hypothesize that radiation is inducing cell death in a
percentage of the population and WIN2 is inducing growth arrest in the remainder. Evaluating
this hypothesis of parallel mechanisms of growth inhibition and cell death in MDA-MB231 and
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4T1 cells in future studies could provide a crucial insight about the interaction between WIN2
and IR in MDA-MB231 and 4T1 cells.

Summary
Section 3 demonstrated WIN2 to possess the ability to significantly augment the
antiproliferative effects of radiation treatment in breast cancer cells in vitro. This section
provided evidence that this augmentation between WIN2 and IR occurs through parallel
mechanisms of growth inhibition. Studies confirmed that radiation treatment induces senescent
growth arrest in MCF-7 cells, which was previously demonstrated by Jones et al. (2005). WIN2
treatment did not elicit a senescent response in MCF-7 cells, nor did it alter the extent of
induction of senescence by radiation, but time course analysis showed a significant growth
delay after WIN2 treatment. Cell death assays (apoptosis, necrosis, autophagy and mitotic
catastrophe) confirm that a low level of cell death cannot explain the growth inhibitory actions of
WIN2. In the absence of overt cell death and senescence, it was concluded that WIN2 causes a
classical growth arrest event as either growth delay or cell cycle arrest. WIN2’s inability to alter
the induction of senescence while still demonstrating augmentation allowed for the conclusion
that WIN2 and IR induce separate but parallel mechanism of growth arrest.
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Section 5
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Establishing the receptor mediating the antiproliferative effects of WIN2

There is well established evidence that the cannabinoid receptors 1 and 2 (CB1 and CB2)
mediate the antiproliferative and/or cytotoxic actions of cannabinoids. CB1 has been shown to
mediate cell death in glioma cells based on the observation that the selective CB1 antagonist
SR141716 inhibited induction of cell death by ∆9-tetrahydrocannabinol (THC) (Salazar et. al
2009). SR141716 also antagonized the growth inhibition of MCF-7 cells by the endogenous
cannabinoid anandamide (AEA) (Melck et al. 2000). This argues for a CB1 mediated mechanism
of growth inhibition by cannabinoids in MCF-7 cells. Even though Melck et al. (2000) found the
expression of CB2 mRNA in MCF-7 cells, the CB2 selective antagonist SR144528 had no effect
on AEA in MCF-7 cells further confirming CB1 actions, but other studies have reported that CB2
mediated growth inhibition of breast cancer cells. In MDA-MB231 breast tumor cells, both
cannabinoid receptor antagonists AM251 and SR144528, CB1 and CB2 respectively, partially
suppressed growth inhibition by WIN55,212-2 (WIN2) in vivo, arguing for CB2 involvement as
well as CB1 in cannabinoid growth inhibition (Qamri et al. 2009). CB2 involvement is supported
by Caffarel et al. 2010, which reported that the CB2 selective agonist, JWH-133, inhibits in vivo
ErbB2 positive mammary tumor growth, and Caffarel et al. 2006, which showed that SR144528
but not SR141716 significantly antagonized the antiproliferative effects of THC in EVSA-T
breast cancer cells in vitro. For these reasons both CB1 and CB2 were evaluated as potential
mediators of WIN2 action in breast tumor cells.
Based on gene reporter assays (O’Sullivan et al. 2007) and antagonist studies (Mestre et
al. 2009) WIN2 is an activator of the peroxisome-proliferator activated receptor γ (PPARγ), and
WIN2 activation of PPARγ induces apoptosis in hepatoma HepG2 cells (Giuliano et al. 2009).
Although WIN2 actions at PPARy in MCF-7 cells have not been assessed, PPARγ has been
found to be expressed in MCF-7 cells (Nwankwo et al. 2001), and continuous treatment with the
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selective PPARy agonist troglitazone inhibited their growth (Yin et al. 2001). Both PPARα and
PPARδ receptor mRNA have also been found in MCF-7 cells (Suchanek et al. 2002a and
2002b). WIN2 has shown activity as an agonist for PPARα by driving luciferase transcription via
a PPARα promoter (Sun et al. 2006). WIN2 action at PPARδ has not been determined and it
remains unclear how PPARα/δ activation would affect MCF-7.
Transient receptor potential-cation-channel subfamily V member 1 (TRPV1) is a nonselective cation channel sensitive to AEA (Smart et al. 2000), and TRPV1 mRNA is found
abundantly in MCF-7 cells (Ligresti et al. 2006). However, TRPV1 involvement in MCF-7 growth
is uncertain. The TRPV1 agonist capsaicin has mixed effects in MCF-7 cells ranging from
minimal (Tuoya et al. 2006) to significant (Thoennissen et al. 2010) growth inhibition.
Furthermore, these studies do not link capsaicin action to TRPV1 either genetically or
pharmacologically. Conversely the TRPV1 antagonist capsazepine sensitizes HCT116 colon
cells to TRAIL induced apoptosis, which argues for a protective action of TRPV1 in cancer
(Sung et al. 2012), but again capsazepine action were not linked to TRPV1 either genetically or
pharmacologically.
The primary aim of the following studies was to determine the potential receptor binding
sites that may mediate the WIN2 antiproliferative action using molecular and pharmacological
techniques. These included CB1 and CB2 receptors, peroxisome proliferator-activated receptors
(PPARα-y), and TRPV1 receptors. RT-PCR was also used to quantify message for GPR55, a
recently discovered cannabinoid sensitive target (Yin et al. 2009, Johns et al. 2007). Summary
of the results presented below, will show WIN2 does not interact with CB1, CB2, PPARα-y or
TRPV1; also no GPR55 message was detected. Studies, based on unpublished data from the
laboratory of Dr. Dana E. Selley, were then performed to evaluate WIN2 potential as an
antagonist of growth pathways activated by sphingosine-1-phosphate, SEW2871 and estradiol.
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*statistical values reported in figure legends

Abbreviations

CB1-cannabinoid receptor 1; CB2-cannabinoid receptor 2; TRPV1-transient receptor potential
cation channel subfamily V member 1; PPAR-peroxisome proliferator-activated receptors; AEAanandamide;

WIN2-WIN55,212-2;

THC-∆9-tetrahydrocannabinol;

phosphate; E2-estradiol; GPCR- G protein coupled receptor
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S1P-sphingosine-1-

Results

Section 5.1 - CB1 and CB2 do not mediate WIN2 elicited antiproliferative effects in MCF-7
cells

As CB1 and CB2 receptor-dependent growth inhibition has been reported in breast cancer
cells (Melck et al. 2000, Qamri et al. 2009), RT-PCR was used to qualitatively confirm the
expression of these receptors in MCF-7 cells. CB2 receptor mRNA was clearly identified, while a
weak signal was found for CB1 (Fig 5.1A). The respective CB1 and CB2 receptor antagonists,
AM251 (4 µM) and AM630 (4 µM) were evaluated for their ability to prevent WIN2-induced
inhibition of cell growth (Fig 5.1B). Neither AM251 nor AM630 antagonized WIN2 growth
suppression. Higher doses of the antagonists could not be used due to inhibition of MCF-7 cell
growth. This lack of antagonism by AM251 and AM630 is strongly indicative of a CB1 and CB2
receptor-independent mechanism.

Section 5.2 - Members of the peroxisome-proliferator activated receptor family do not
mediate WIN2 elicited antiproliferative effects in MCF-7 cells

Given the apparent lack of CB1 and CB2 receptor involvement in the antiproliferative
effects of WIN2 (section 5.1), the contribution of other WIN2 sensitive targets were assessed.
RT-PCR confirmed the presence of PPARγ mRNA in MCF-7 cells (Fig 5.2A), but the PPARγ
receptor antagonist GW9662 (10 µM) did not reduce the antiproliferative effects of 12 µM WIN2
(Fig 5.2B). The PPARγ receptor agonist pioglitazone (PGZ) and pan-PPAR agonist bezafibrate
were tested for antiproliferative activity in MCF-7 cells (Fig 5.2C-D), but neither recapitulated
WIN2 growth inhibition further confirming WIN2 is not inhibiting MCF-7 growth via PPAR
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Figure 5.1 – The antiproliferative effects of WIN2 in MCF-7 cells are mediated through a
non-cannabinoid receptor mechanism of action. (A) RT-PCR for the CB1 and CB2 receptors
in MCF-7 cells. CHO cells transfected with human CB1 or CB2 receptors were used as a positive
control. (B) MCF-7 cells were treated with vehicle or WIN2 (12 µM) and vehicle, AM251 (4 µM),
or AM630 (4 µM) for 24 h. Cell count with trypan blue was used to assess cell viability at 96 h.
Data presented reflect the means of 3 individual experiments + se; no significant difference
found. None transformed control viable cell numbers as mean +se - 2247442+746329
Statistics
(B) Two way repeated measures ANOVAs: AM251-WIN2 interaction - (p=0.7429);
AM630-WIN2 interaction - (p=0.4901).
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Figure 5.2 – PPAR receptor activation does not mediate WIN2 effects in MCF-7 cells. (A)
RT-PCR for PPARγ (B) MCF-7 cells were treated with vehicle or WIN2 (12 µM) and vehicle or
GW9662 (10 µM). (C) MCF-7 cells were treated with vehicle or WIN2 (12 µM) and vehicle or
pioglitazone (40 µM). (D) MCF-7 cells were treated with bezafibrate (0-100 µM) and vehicle or
WIN2 (12 µM) . Cells count with trypan blue was used to assess cell viability at 96 h (A, B and
C). Crystal violet assessed population density at 96 h (D). Data presented reflect the means of 3
individual experiments + se; no significant difference found.
Statistics
(B) Two way repeated measures ANOVA: GW9662-WIN2 interaction (p=0.3208).
(C) Two way repeated measures ANOVA: PGZ-WIN2 interaction (p=0.1670). PGZ
treatment main effect (p=0.5385).
(D) Two way repeated measures ANOVA: Bezafibrate-WIN2 interaction (p=0.9981).
Bezafibrate treatment main effect (p=0.8611).
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receptor activation. PGZ and bezafibrate also had no effect on the WIN2-mediated growth
inhibition when given in combination (Fig 5.2 C-D). Together these experiments show that WIN2
fails to activate or antagonize all members of the PPAR receptor family.

Section 5.3 - TRPV1 is not involved in WIN2 mediated antiproliferative actions in MCF-7
cells

TRPV1 was evaluated as a potential target of WIN2 action after other well established
WIN2 sensitive targets were experimentally eliminated. RT-PCR confirmed the presence of
mRNA for TRPV1 in MCF-7 cells (Fig 5.3A), but the TRPV1 receptor antagonist capsazepine
(10 µM) failed to reduce the antiproliferative effects of WIN2 (Fig 5.3 B). Furthermore, 100 µM
of the TRPV1 agonist capsaicin (CAP) failed to elicit antiproliferative activity alone (p=0.1410;
Fig 5.3C). CAP was also given in combination with WIN2 (Fig 5.3C), but no significant
interaction between treatments was found. These studies indicate that WIN2 was unlikely to be
inhibiting the growth of MCF-7 cells via interaction with the TRPV1 receptor.

Section 5.4 - GPR55 mRNA is not found in MCF-7 cells

WIN2 has not been shown to activate GPR55 (Johns et al. 2007, Yin et al. 2009), but
AEA, THC and CP55,940 activated GPR55 using a β-arrestin or GPR55 activated luciferase
reporter assay (Yin et al. 2009). However, depending on the study, the cannabinoid agonist
abnormal-cannabidiol showed both a neutral activity (Yin et al. 2009) and agonist activity (John
et al. 2007) at GPR55. This suggests a system specific effect of some cannabinoids at GPR55.
Therefore, GPR55 was assessed as a potential target for the anti-proliferative actions of WIN2
in MCF-7 cells. RT-PCR qualitatively proved that no GPR55 mRNA was detectable in MCF-7
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Figure 5.3 – WIN2 has no interaction with TRPV1 in spite of its mRNA expression in MCF7 cells. (A) RT-PCR for TRPV1 (B) MCF-7 cells were treated with vehicle or WIN2 (12 µM) and
vehicle or capsazapine (10 µM). (C) MCF-7 cells were treated with vehicle or WIN2 (12 µM) and
vehicle or capsaicin (100 µM). Cell count with trypan blue was used to assess cell viability at 96
h. Data presented reflect the means of 3 individual experiments + se; no significant difference
found.
Statistics
(B) Two way repeated measures ANOVA: CPZ-WIN2 interaction (p=0.2164)
(C) Two way repeated measures ANOVA: CAP-WIN2 interaction (p=0.8076). CAP
treatment main effect (p=0.1410)
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Figure 5.4 – GPR55 mRNA was not found in MCF-7 cells. Representative blot of three.
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cells (Fig 5.4), and a lack of GPR55 expression eliminated the need for further assessment of
its involvement in WIN2 mediated anti-proliferative actions.

Section 5.5 - MCF-7 cell sensitivity to growth inhibition by WIN2 is increased under
serum free conditions

Studies to be presented next will utilize a low serum condition. Pertinent to this,
Jacobsson et al. (2001) reported that AEA has different potencies for inhibiting C6 glioma cell
growth depending on the serum concentration used in media. To assess the antiproliferative
and stereospecific actions of WIN2 under low serum conditions, dose-responses for WIN2 and
its inactive enantiomer WIN55,212-3 (WIN3) were compared using 0.1% serum conditions (Fig
5.5). Comparison of WIN2 and WIN3 show that WIN2 retains it dose-dependent and
stereospecific inhibition of MCF-7 cell growth under low serum conditions, and comparisons of
the ED50 for WIN2 under low (3.13+0.29 µM) and normal (11.96+1.65 µM) serum also show
WIN2 to be more potent under low serum with a potency ratio of 3.39 relative to normal serum
conditions. The ED50 for WIN2 in normal serum was reported in section 3.1.

Section 5.6 - WIN2 antagonizes growth stimulation by sphingosine-1-phosphate and
SEW2871 but not estradiol

Unpublished studies by Dr. Dana E. Selley suggested WIN2 has actions at the
sphingosine-1-phosphate (S1P) system, and the S1P signaling system has been shown
important to the proliferation of MCF-7 cells (Sarkar et al 2005). These data suggested that
WIN2 inhibited MCF-7 cell growth through activity at S1P receptors; therefore studies were
designed to evaluate the S1P system as a potential site for the antiproliferative actions of WIN2
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Figure 5.5 – Influence of low serum (0.1%) conditions on response of MCF-7 cells to WIN2
and WIN3. MCF-7 cells were treated with WIN2 (1-10μM) and WIN3 (1-10μM) and cell growth
monitored by the crystal violet assay 96 h after treatment. Data presented reflect the means of 3
individual experiments + se; *=p<0.05 vs WIN3 at each respective concentration of drug;
darkened symbols=p<0.05 vs vehicle.
Statistics
Two way repeated measures ANOVA: drug-dose interaction (F10,22=9.6, p<0.0001)
Individual comparisons: WIN2-WIN3 4-10 µM (p<0.025). WIN2-vehicle 5-10 µM
(p<0.025). WIN3-vehicle (no significant differences)
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Figure 5.6 – WIN2 interferes with sphingosine-1-phosphate induced growth stimulation.
MCF-7 cells were incubated under low serum conditions with 100 nM sphingosine-1-phosphate
± WIN2 (3 µM). Trypan blue exclusion was used to assess cell viability at 96 h post treatment.
Values are presented as percent of control and represent means+se for 3-4 replicate
experiments; * p<0.05 vs vehicle; #p<0.05 indicated by bars.
Statistics
Two way repeated measures ANOVA: WIN2-S1P interaction (F1,4=20.8, p=0.0103)
Individual comparisons: S1P-vehicle (p=0.0302). Vehicle-WIN2 (no significant difference).
S1P-WIN2 + S1P (p=0.0074).
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in MCF-7 cells. Under low serum conditions of 0.1 percent serum, 100 nM S1P stimulated MCF7 cell growth, which was subsequently suppressed by WIN2 (3 µM); this concentration of WIN2
was not able to inhibit basal cell growth by itself (Fig 5.6).
In complementary studies, a sub-effective dose of WIN2 (8 µM) under normal serum
conditions prevented the growth stimulatory effects SEW2871 (5 µM), the synthetic S1P1
receptor-selective agonist (Fig 5.7A). In contrast, 25 µM THC failed to inhibit growth stimulation
by SEW2871 (Fig 5.7B). The differential actions of WIN2 and THC indicate that not all
cannabinoids are capable of antagonizing SEW2871 induced breast tumor cell growth. To
explore the possibility that WIN2 might be interfering with another growth stimulatory pathway,
cells were exposed to 100 nM estradiol in the absence and in the presence of 8 µM WIN2 (Fig
5.8); however, WIN2 failed to antagonize the growth stimulating effects of estradiol. In summary,
these studies show that WIN2 antagonism of growth stimulation appears to be selective for the
S1P signaling system.

Section 5.7 - WIN2 does not antagonize S1P-stimulated [35S]GTPγS binding

Agonist-stimulated [35S]GTPγS binding assays were used to test the ability of WIN2 to
antagonize S1P stimulated G protein activation. S1P (0.1,1 and 10 µM) was incubated alone or
in combination with WIN2 (30 µM; Fig 5.9). WIN2 was unable to alter S1P-stimulated
[35S]GTPγS binding, which may or may not suggest WIN2 has capacity to antagonize S1P
signaling at S1P receptors (further elaboration in discussion). WIN2 stimulated [35S]GTPγS
binding was also not found to be significantly greater than basal levels. The S1P receptor
system has 5 receptors (Rosen et al. 2009), and Dr. Dana Selley’s work has implicated WIN2 as
a partial agonist at S1P1 receptors. The inability of WIN2 to stimulate [35S]GTPγS binding in
MCF-7 cells could reflect that S1P1 receptors are not present in MCF-7 cells or that S1P1
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receptors are not present in high enough density compared to other S1P receptors to allow
detection.
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Figure 5.7 – WIN2 but not THC interferes with SEW2871 induced growth stimulation.
MCF-7 cells were incubated with (A) 5 µM SEW2871 ± 8 µM WIN2 or (B) 5 µM SEW2871 ± 25
µM. Trypan blue exclusion was used to assess cell viability at 96 h post treatment. Values are
presented as % of control and represent means+se for 3-4 replicate experiments; * p<0.05 vs
vehicle; #p<0.05 indicated by bars.
Statistics
(A) Two way repeated measures ANOVA: WIN2-SEW2871 interaction (F1,4=36.3,
p=0.0038)
(A) Individual comparisons: Vehicle-SEW2871 (p=0.0254). Vehicle-WIN2 + SEW2871
(p=0.0416). SEW2871-WIN2 + SEW2871 (p=0.0038)
(B) Two way repeated measures ANOVA: THC-SEW2871 interaction (p=0.5969).
SEW2871 treatment main effect (F1,4=19.7, p=0.0113)
(B) Individual comparisons: Vehicle-SEW2871 (p=0.0178). Vehicle-WIN2 + SEW2871
(p=0.0131).
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Figure 5.8 – WIN2 fails to interfere with estradiol induced growth stimulation. MCF-7 cells
were incubated with 100 nM estradiol ± 8 µM WIN2. Trypan blue exclusion was used to assess
cell viability at 96 h post treatment. Values are presented as % of control and represent
means+se for 3-4 replicate experiments; * p<0.05 vs vehicle; #p<0.05 indicated by bars.
Statistics
Two way repeated measure ANOVA: WIN2-Estradiol interaction (p=0.7317). Estradiol
treatment main effect (F1,6=14.4, p=0.0090)
Individual comparisons: Vehicle-estradiol (p=0.0062). Vehicle-WIN2 + estradiol
(p=0.0098).
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Figure 5.9 – WIN2 does not antagonize S1P stimulated G protein activation. Sphingosine1-phosphate stimulation of [35S]GTPγS binding (0.1-10 µM) + 30 µM WIN2. WIN2 was also
tested alone as a control. Data presented as % stimulation and represent mean+se for 3-7
replicate experiments. No significant differences detected between S1P and S1P + WIN2.
Statistics
Two way repeated measures ANOVA: WIN2-S1P interaction (p=0.3580). S1P treatment
main effect (F1,21=9.5, p=0.0011)
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Discussion

Known cannabinoid sensitive targets are not mediating WIN2 effects

In the current studies, WIN2 was not antagonized by the CB1 selective antagonist AM251.
This is surprising because the CB1 selective antagonist SR141716 suppressed AEA inhibition of
MCF-7 cell growth in Melck et al. 2000. Both WIN2 and AEA are agonists for the CB 1 receptor
and should mimic each other’s actions at CB1 (Sim et al. 1996, Showalter et al. 1996). The most
likely explanation for this discrepancy is the differences between mRNA expression of CB1 in
MCF-7 cells between the studies. Melck et al. reported a clear expression of CB1 message in
MCF-7 cells while my work showed a poorly detected level of CB1 message. This is unexpected
but differences in RT-PCR results within MCF-7 cells are not unfounded. Varying RT-PCR
results in MCF-7 cells include a strong signal for both CB1 and CB2 (Melck et al. 2000), low
expression of both (Ligresti et al. 2006), no expression of either (Takeda et al. 2008), CB 1
(McKallip et al. 2005) or CB2 alone (Caffarel et al. 2006). Differences in the RT-PCR protocol
could explain the differences in CB1 expression reported in the presented studies compared to
Melck et al., but they would not explain the inability of AM251 to antagonize WIN2 here and full
reversal of AEA growth inhibition by SR141716 in Melck et al. Two more likely explanations are
that either WIN2 is more potent at a secondary target, which is masking WIN2 actions at those
CB1 receptors present, or the expression of CB1 in MCF-7 cells is different between these
studies due to genomic differences in the cell lines.
Published reports support the possibility of genomic differences between Melck et al.’s
work and the work presented above. One study demonstrated that genomic instability can
contribute to cancer progression by showing that subclones of the murine fibrosarcoma UV2237 derived at different times after thawing of stock cells had significant differences in their
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metastatic potential when injected into C3H mice (Cifone and Fidler et al. 1981). A more recent
demonstration linked genetic instability to alterations in tumor population heterogeneity.
Masramon et al. 2006 used DNA fingerprinting by arbitrarily primed PCR in various colon cancer
cell lines (SW480, LoVo and HT116) to measure increases in heterogeneity in each population
after clonal expansion when compared to parent cells. Genomic instability manifesting as
changes in genetic heterogeneity could easily explain the variability in cannabinoid receptor
expression between the studies described above: Melck et al. 2000, Ligresti et al. 2006, Takeda
et al. 2008, McKallip et al. 2005, Caffarel et al. 2006. Nevertheless, based on the present work it
can be concluded that WIN2 is not acting via CB1 under the current experimental conditions.
In the present studies, WIN2 failed to interact with CB2, PPARy and TRPV1, all of which
have previously been shown to mediate potential antiproliferative roles in cancer (Qamri et al.
2009, Caffarel et al. 2010, Yin et al. 2001, Thoennissen et al. 2010). Although message for all
three receptors was identified by RT-PCR, the antagonists AM630 (CB2), GW9662 (PPARy) and
capsazepine (TRPV1) failed to antagonize WIN2 action (Walpole et al. 1994, Ross et al. 1999,
Bendixen et al. 2001). The agonists, pioglitazone (PPARy) and capsaicin (TRPV1), also failed to
recapitulate antiproliferative effects of WIN2 when administered to MCF-7 cells with the same
drug treatment protocol used for WIN2. PPARα/δ are known to be expressed in MCF-7 cells
(Suchanek et al. 2002a and 2002b), but bezafibrate, the pan-PPAR agonist, also failed
recapitulate WIN2 inhibition of MCF-7 cell growth. In the end, these studies indicate that CB2,
TRPV1 and all members or the PPAR family are not involved in the antiproliferative effects of
WIN2.
Convergent lines of evidence eliminate the possibility of GPR55 involvement in WIN2
mediated effects. β-arrestin luciferase reporter assay and GPR55 activated luciferase reporter
assay in transfected Hek-293 cells (Yin et al. 2009), as well as [35S]GTPγS binding assays in
HEK-293T cell over expressing GPR55 (Johns et al. 2007), have shown GPR55 to be sensitive
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to a variety of cannabinoids. However, WIN2 was unable to activate GPR55 in either of these
studies suggesting it may not be an agonist for GPR55. In addition, GPR55 has been linked to
tumor growth stimulating effects. Expression of GPR55 in human tumors was correlated with
decreased patient survival, overexpression of GPR55 in HEK, EVSA-T and T98G cells
increased growth rates, and GPR55 knockdown decreased growth rates in EVSA-T and T98G
cells (Andradas et al. 2011). These growth stimulating effects of GPR55 were further supported
by Pineiro et al. (2011) when genetic knockdown of GPR55 decreased growth rates in PC-3 and
OVCAR3 cells. However, the strongest evidence for lack of GPR55 involvement in WIN2 growth
inhibition is that RT-PCR indicated no GPR55 message present in MCF-7 cells utilized in these
studies.

WIN2 acts through the sphingosine-1-phosphate fatty acid signaling network

S1P is present at concentrations between 0.1 µM in fetal bovine serum used for culturing
and 0.8-1 µM in human plasma (Murata et al. 2000), and can be synthesized intracellularly by
sphingosine kinase 1 (cytoplasmic/membrane) and 2 (nuclear) (Rosen et al. 2009). S1P is also
known to activate the 5 known S1P G protein coupled receptors (GPCRs), S1P1-5, (Rosen et al.
2009). S1P has been implicated in a host of disease processes including arthritis, asthma,
atherosclerosis, cancer, diabetes and osteoporosis (Maceyka et al. 2012, Orr Grandy et al.
2012). Cancer related effects of S1P include increased proliferation, cell transformation, cell
death evasion, drug resistance, inflammation, metastasis and angiogenesis (Takabe et al. 2008,
Pyne et al. 2010). In MCF-7 breast cancer cells, knocking down sphingosine kinase 1 (SPK1)
depresses chemotactic migration, increases apoptosis after adriamycin treatment and
decreases proliferative rates (Sarkar et al. 2005). Western blotting and RT-PCR in MCF-7 cells
demonstrates strong expression of S1P3, which has been identified as a mediator of SPK1
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growth stimulating properties (Wang et al. 1999, Sukocheva et al. 2006, Hadizadeh et al. 2008,
Sukocheva et al. 2013). RT-PCR analysis identified S1P2 expression in MCF-7 cells, although to
a lesser extent than S1P3, and conflicting reports suggest S1P1 may or may not be expressed
(Wang et al. 1999, Hadizadeh et al. 2008, Sukocheva et al. 2013). Unlike S1P3, S1P1 & 2 have
not been assessed for pro-growth or survival activity in MCF-7 cells. One report also identified
S1P receptor-independent effects in MCF-7 cells for S1P inhibition of motility (Wang et al.
1999), which indicates further undiscovered complexity present in the S1P signaling system.
In the current work a sub-effective dose of WIN2 antagonized growth stimulation by S1P
and the synthetic S1P1 receptor agonist SEW2871 in MCF-7 cells. Antagonism of S1P and
SEW2871 indicates that WIN2 actions interact at some point along the S1P signaling pathway,
although it cannot be determined if this interaction is direct or indirect. Interestingly, THC failed
to antagonize SEW2871 growth stimulation demonstrating that antagonism of S1P signaling is
not a function that generalizes to all cannabinoids. This lack of generalized effects for S1P
action across cannabinoid agents might explain why WIN2 and the other aminoalkylindoles
were unique in their ability to augment the anti-proliferative effects of radiation. Therefore, it is
possible that antagonism of S1P signaling is required for augmentation of the antiproliferative
actions of radiation in MCF-7 cells. Future studies should address this possibility starting with
testing the other two aminoalkylindoles shown to augment the antiproliferative effects of
radiation, JWH-015 and pravadoline, in combination with S1P and SEW2871. Future studies
should also evaluate WIN2 interactions with S1P signaling in combination with radiation
treatment, although, this will be easier to test once the interaction between WIN2 and S1P
system is more fully understood.
Although a specific intersection between WIN2 actions and S1P growth signaling has not
been identified by these studies, multiple lines of evidence narrow the pool of potential sites of
action. WIN2 antagonism of S1P or SEW2871 growth stimulation and lack of interference with
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estradiol-induced growth stimulation demonstrates that WIN2 is not antagonizing cell cycle
machinery utilized by both growth stimulating pathways. Additionally, WIN2 antagonism of
exogenous S1P or SEW2871 shows that WIN2 is not altering intracellular S1P synthesis or
degradation. As a result, WIN2 is likely to be acting on the S1P receptors, intracellular signaling
machinery that is downstream of the S1P receptor, or an alternate pathway that intersects with
the S1P signaling system.
Evaluating WIN2 actions at S1P receptors is the likely place to start based on
unpublished work from our collaborator, Dr. Dana Selley, which indicates that WIN2 acts as a
partial agonist at S1P1 receptors. S1P1 is potentially expressed in MCF-7 cells, as discussed
above (Wang et al. 1999, Hadizadeh et al. 2008, Sukocheva et al. 2013), and if WIN2 acts as a
partial agonist at S1P1 it could also act as a partial antagonist, explaining the observations seen
with WIN2 in the studies presented in this work. However, when considering what is known
about S1P receptors in MCF-7 cells, evaluating the hypothesis that WIN2 is a partial antagonist
for S1P receptors becomes challenging. First, it is unknown if S1P1 receptors are involved in
growth signaling in MCF-7 cells. Second, S1P3 receptors have been linked to growth stimulation
in MCF-7 cells (Sukocheva et al. 2006, Sukocheva et al. 2013), but Dr. Dana Selley’s work has
not clearly addressed if WIN2 has actions at S1P3 receptors. Additionally, those reports
demonstrated S1P3 associated growth stimulation as an intermediary of non-genomic estrogen
growth signaling (Sukocheva et al. 2006, Sukocheva et al. 2013). Finally, while S1P3 receptors
might be the dominant S1P receptor in MCF-7 cells and a mediator of estrogen growth
stimulation, studies presented in this document have demonstrated that WIN2 antagonism of
S1P growth stimulation is estrogen independent in nature, which would suggest S1P3 is not
involved in the WIN2 mediated antagonism of S1P growth stimulation. Furthermore, WIN2
antagonized growth stimulation by the S1P1 receptor selective agonist SEW2871 (Sanna et al.
2004), which does argue for an S1P1 dependent mechanism.
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[35S]GTPγS binding studies were used to potentially answer some of these questions, but
WIN2 could neither significantly stimulate [35S]GTPγS binding alone, nor could it antagonize
S1P stimulated [35S]GTPγS binding. At first, these results suggest that WIN2 it not acting as a
partial agonist/antagonist at S1P receptors but there are other possibilities to consider. The
most obvious is that the duration of WIN2 treatment in the [35S]GTPγS binding and cell count
studies are different, 2 vs. 24 h respectively, and therefore the [35S]GTPγS binding studies do
now accurately mimic observations from the cell count studies. It is also possible that the
kinetics for [35S]GTPγS binding are different between S1P receptors, and the [35S]GTPγS
binding studies presented here are demonstrating a preference for one S1P receptor over the
other providing an incomplete pictures of WIN2 action. Another possibility is that S1P1 receptors
are expressed at considerably lower levels than S1P3 receptors, and the [35S]GTPγS binding
assay is simply not sensitive enough to detect actions at these receptors. Any of these
eventualities would prevent the [35S]GTPγS binding assay from being able to determine if WIN2
is acting at S1P1 as either a partial antagonist, which would inhibit S1P signaling, or as a partial
agonist which would cause receptor downregulation, effectively silencing the S1P system.
Future studies could address these possibilities. qRT-PCR and western blotting could identify
the S1P receptors present in these MCF-7 cells and determine whether WIN2 has effects on
the levels of receptor expression after treatment. Selective genetic knockout or pharmacological
antagonism of S1P receptors can detect if WIN2 antagonism of S1P growth stimulation is
mediated through a specific S1P receptor. Also, further [35S]GTPγS binding studies using longer
incubation times and either genetic knockdown or pharmacological antagonism of S1P3
receptors could more accurately test the involvement of S1P1 receptors in MCF-7 cells,
assuming qRT-PCR and western blotting can confirm their expression.
It does also remain possible that WIN2 actions are not mediated by the S1P receptors,
and WIN2 actions occur either further downstream of the receptor or in a secondary pathway
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that antagonizes S1P signaling indirectly. For instance, growth stimulation by S1P occurs
through RAS signaling. When SPK1 is antagonized and knocked down in T24 bladder cancer
cells, RAS-GTP is decreased (Shu et al. 2001). Based on the involvement of RAS in S1P
dependent cell growth, as well as WIN2 demonstration of classical growth arrest in section 4 of
this document, RAS is a logical candidate for future studies examining the effects of WIN2 in
MCF-7 cells. AKT is another possible target based on work from Park et al. (2011), who
reported a WIN2 induced G1 cell cycle growth arrest in gastric cancer cell that was rescued by
overexpression of active myristoylated-AKT. Lastly, Osawa et al. (2001) showed that S1P
treatment protected hepatoma cells from apoptosis and increased p-AKT expression, while
SPK1 antagonism increased apoptosis and decreased p-AKT expression. Based on these two
studies AKT should also be considered a candidate for evaluation in future studies.
A substantial amount of work remains to accurately identify the site of action for WIN2 in
MCF-7 cells, and whether that site of action is responsible for the observed augmentation of
radiation by WIN2 presented in previous chapters. Nevertheless, it can be concluded from the
work presented here that WIN2 has actions that intersect with and antagonize the S1P signaling
system.

Summary

Section 3 of this document showed that WIN2 was able to augment the antiproliferative
actions of radiation in MCF-7 cells, and section 4 attributed this augmentation to parallel
mechanisms of growth arrest. This section, section 5, was focused on elucidating the receptor
mediating WIN2 signaling in MCF-7 cells. RT-PCR and pharmacological analysis was used to
exclude the involvement of known cannabinoid sensitive targets CB1, CB2, PPARα-γ, TRPV1
and GPR55. WIN2 antagonism of S1P associated growth stimulation, however, indicated a
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novel site of action for WIN2 in MCF-7 cells that interacts with or is present in the S1P signaling
system. Future studies are still required to determine the novel site of actions and confirm that
WIN2 actions at this site mediate the WIN2/IR augmentation.
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Section 6
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Summary, Discussion and Future Studies

The primary findings of this work are that WIN55,212-2 (WIN2) has the capacity to
augment the antiproliferative effects of radiation in breast tumor cells, and that other
cannabinoids that fail to have this effect do not interfere with the actions of radiation. Studies in
MCF-7 cells were confirmed in MDA-MB231 cells and 4T1 cells. WIN2 augmentation of the
antiproliferative effects of radiation were also shown to be stereospecific using the inactive
enantiomer of WIN2, WIN55,212-3 (WIN3). These findings serve as effective proof of principle
that WIN2, or similar compounds could enhance patient survival if given in combination with
radiation, but due to complications with the in vivo studies, discussed below, it remains
imperative that future studies expand this work beyond the in vitro models used here.
Opposite to its combination with radiation, WIN2 failed to augment the effects of
doxorubicin (Adriamycin) in MCF-7 cells. As is the case with radiation, ADR induces
senescence in MCF-7 cells (Jones et al. 2005; Goehe et al. 2012). One possible explanation for
why WIN2 enhanced the antiproliferative effects of radiation but not doxorubicin is that
senescence induced by doxorubicin is different than senescence induced by radiation. Bristol et
al. (2012) demonstrated that blockade of autophagy after radiation treatment forced the cells to
switch from an entirely senescent response to cell death through apoptosis, while Goehe et al.
(2012) demonstrated blockade of autophagy after ADR treatment only caused a delay in the
onset of senescence without a significant enhancement of the antiproliferative effects of ADR.
With these differing reports of senescent responses in MCF-7 cells, it cannot be assumed that
WIN2 actions will interact with radiation and ADR in the same way.
The mechanism of action for the WIN2/IR combination identified in vitro was studied
primarily in the MCF-7 cell model. Radiation-induced senescence, assessed by β-galactosidase
staining, confirmed previous findings of radiation-induced senescence (Jones et al 2005);
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however, WIN2 had no effect on the extent of senescence induction. Quantification of DNA
damage and repair by γH2AX labelling also indicated that WIN2 did not increase the extent of
DNA damage or interfere with cellular repair of DNA elicited by radiation treatment. Salazar et
al. (2009) showed that a ∆9-tetrahydrocannabinol (THC) treatment in U87-MG glioblastoma
induced autophagy that was toxic to tumor cells, and studies presented here show autophagy
was clearly induced by both radiation and WIN2. However, pharmacological blockade of
autophagy did not interfere with the effectiveness of the combination treatment, demonstrating
that cellular sensitivity to radiation was not augmented by WIN2 via autophagy. Annexin V and
PI staining combined with DAPI imaging of nuclear morphology demonstrated that apoptosis,
necrosis and mitotic catastrophe were not induced by the WIN2/IR combination. When the
effects of the WIN2/IR combination on senescence are considered in the absence of cell death,
it can be concluded that WIN2 is likely to be inducing classical growth arrest, either as a growth
delay or cell cycle arrest type event, and this is confirmed by temporal studies. Additionally, this
classical growth arrest conclusion combined with the temporal studies indicates that the
augmentation of the antiproliferative effects of radiation by WIN2 is mediated by parallel
mechanisms of classical growth arrest (WIN2) and senescent growth arrest (IR).
Subsequent studies were designed to identify the receptor(s) mediating the
antiproliferative actions of WIN2 in breast tumor cells. Although expression of CB1, CB2, PPARy
and TRPV1 were shown in the MCF-7 cells, pharmacological experiments using various
agonists and antagonists of these selected receptor pathways demonstrated that CB1, CB2,
PPARy and TRPV1 were not mediating the antiproliferative effects of WIN2. Pharmacological
experiments were extended to show that PPARα-γ were also not involved in the antiproliferative
mechanism of WIN2. GPR55 was excluded as a potential target based on a lack of receptor
expression, as well as reports that GPR55 supports tumor growth and does not interact with
WIN2 (Johns et al. 2007; Yin et al. 2009; Andradas et al. 2011; Pineiro et al. 2011; Perez131

Gomez et al. 2012). Previous work in CB1 knockout brains has demonstrated that WIN2 has
actions at a GPCR that is as of yet unidentified in the literature, which supports the possibility
that WIN2 is acting at a novel site of action (Brievogel et al. 2001). With all known cannabinoid
sensitive targets eliminated as potential sites of action for WIN2, studies were designed to
address possible interactions with sphingosine-1-phosphate (S1P) (Selley D., unpublished
data).
A sub-effective dose of WIN2 antagonized growth stimulation by S1P receptor agonists
(S1P and SEW2871) in MCF-7 cells; this finding connects the antiproliferative properties of
WIN2 to the S1P signaling pathway, but it does not identify a specific target of action. Several
complementary lines of evidence did, however, narrow the pool of potential candidate sites. For
example, WIN2 did not antagonize the growth stimulating effects of estradiol, confirming that the
mechanism for WIN2 is specific to S1P signaling. Also, WIN2 antagonism of exogenous S1P
and SEW2871 shows that WIN2 is not altering intracellular S1P synthesis or degradation.
[35S]GTPγS binding studies were attempted to confirm or refute the involvement of WIN2
actions at the S1P receptors, but limitations of the studies prevent a conclusion of this nature.
Future studies are still requires assess WIN2 actions at or on the S1P receptors present within
MCF-7 cells.
It is also possible that WIN2 is directly antagonizing a downstream component of the S1P
signaling system, but this cannot be concluded since WIN2 could be acting outside of the S1P
signaling pathways causing alterations to the S1P signaling system indirectly. One example of
this type of indirect mechanism is the inhibition of MCF-7 growth by methanandamide (MAEA)
reported by Laezza et al. (2006; 2010). MAEA treatment caused down regulation of HMG-CoA
reductase leading to decreases in pools of mevalonic acid and prevented various proteins from
trafficking to the membrane from the cytosol, one of which included the well-known growth
stimulating protein RAS. This indirect down regulation of RAS by MAEA was shown to inhibit
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growth of MCF-7 cells. Although WIN2 may cause down regulation of RAS in MCF-7 cells, it is
unlikely that WIN2 would do so by down regulating HMG-CoA reductase. MAEA was shown to
down regulate HMG-CoA via a CB1 dependent mechanism in Laezza et al. 2006, and studies
presented in this document demonstrated that CB1 is not involved in the actions of WIN2.
Nevertheless, based on the classical growth arrest mechanism associated with WIN2 in MCF-7
cells presented here, and Shu et al.’s (2001) demonstration of S1P signaling through RAS, it
would be logical to evaluate RAS under WIN2 treatment. Initial studies would determine RAS
levels and activity after vehicle, WIN2, IR and WIN2 + IR treatments.
A second potential target was identified in studies reported by Park et al. (2011), where
WIN2 induced AKT down regulation and a G1 cell cycle growth arrest in gastric cancer cells that
were rescued by overexpression of active myristoylated-AKT. Caffarel et al. (2010) also showed
AKT dependent growth inhibition where overexpression of AKT in N202.1A breast cancer cells
prevented both THC and JWH-133 from inhibiting cell growth. Furthermore, S1P signaling was
connected to AKT in hepatoma cells where S1P administration decreased apoptosis and
increased p-AKT expression, and antagonism of the kinase responsible for S1P production,
sphingosine kinase 1, increased apoptosis and decreased p-AKT expression (Osawa et al.
2001). Quantifying AKT and p-AKT levels after vehicle, WIN2, IR and WIN2 + IR treatment in
MCF-7 cells would evaluate potential involvement of AKT in the WIN2 mediated mechanism of
growth inhibition.
There still remains a great deal of work to do before identification of the site of action for
WIN2 can be elucidated conclusively. These studies may also include broader studies that
utilize microarray, proteomic or metabolomic work to identify novel targets and non-canonical
mechanisms that were not hypothesized here, and even when this site of action is identified it
must still be connected to the WIN2 mediated augmentation of radiation. Nevertheless it can be
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concluded from the work presented in this document that WIN2 has the capacity to interact with
the S1P signaling system in some capacity to affect growth.
In addition to MCF-7 cells, discussed above, studies were completed using the WIN2/IR
combination in the MDA-MB231 cell line where WIN2 demonstrated significant augmentation of
the antiproliferative effects of radiation. Similar to the augmentation in MCF-7 cells, the
augmentation in MDA-MB231 cells was also confirmed to be stereospecific in nature using
WIN3. Time course studies showed that a growth inhibitory phenotype was present in MDAMB231 cells as was present in MCF-7 cells. Mechanistic studies were not performed in MDAMB231 cells, in part due to the differences in the reported mechanisms of action for radiation in
MCF-7 and MDA-MB231 cells, senescence and apoptosis respectively (Jones et al. 2005).
Identification of a target of action for WIN2 in MCF-7 cells could guide receptor evaluations in
MDA-MB231 cells, but until a novel site of action is elucidated all cannabinoid sensitive targets
(CB1, CB2, PPARα-y, TRPV1 and GPR55) must be systematically evaluated in MDA-MB231
cells just as they were in MCF-7 cells. This systematic evaluation would also include the
interaction between WIN2 and S1P growth stimulation.
The WIN2/IR combination also augmented the effects of radiation in 4T1 cells in vitro.
However, in vivo studies using the 4T1-Balb/c syngeneic tumor growth model failed to show
augmentation of the antiproliferative effects of radiation by WIN2. However, this lack of
augmentation was likely confounded by the fact that WIN2 did not inhibit tumor growth alone in
these animals, which was entirely unexpected since the dose of WIN2 used in the combination
study was based on a previous dose-response study in the 4T1-Balb/c model where WIN2
significantly inhibited tumor growth. It is unclear why WIN2 failed to replicate its inhibition of
tumor growth in vivo between the two studies, and, to date, no variables have been identified
that could explain the differences between the studies. Studies should be conducted to
ascertain the effects that WIN2 and IR have in combination using a whole animal, but future
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efforts utilizing the MCF-7 model in immune compromised mice implanted with estrogen pellets
might prove to be a better approach.
Contrasting the breast cancer cells used (MCF-7, MDA-MB231 and 4T1 cells), MCF-10A
cells are a non-transformed immortalized breast epithelial cell line that was used in these
studies to test the ability of WIN2 to augment the toxicities of radiation to normal cells. While
high doses of WIN2 (30 μM) did augment radiation mediated antiproliferative actions in MCF10A cells, the dose of WIN2 used in the MCF-7 cell studies (12 μM) was unable to elicit growth
inhibition by WIN2 alone or in combination with radiation in MCF-10A cells. This finding
demonstrates that WIN2 is less potent in the non-transformed MCF-10A cells, and this lower
potency suggests a therapeutic window in treatment that would create selectivity for cancer cells
over normal tissue. As non-cancerous tissues in the body exist largely in a non-proliferative
state, if WIN2 is acting through a classical growth arrest mechanism without inducing cell death,
then adverse effects on non-cancerous tissue would be even more unlikely to occur in the whole
animal. Nevertheless, future studies should be performed using proliferating non-cancerous
tissues such as gastrointestinal epithelial cells to determine if WIN2 is capable of antagonizing
their growth, because unlike focused irradiation, WIN2 will be distributed throughout the body by
systemic blood circulation.
In addition to testing the WIN2/IR combination in multiple cells lines, multiple
cannabinoid/IR combinations were tested in MCF-7 cells. These include THC, CBD, nabilone,
CP55,940 and methanandamide, which all failed to interact with radiation in MCF-7 cells. The
aminoalkylindoles, JWH-015 and pravadoline however, significantly augmented the effects of
radiation at the highest concentrations tested (45 μM). Later studies showed that WIN2
antagonized S1P stimulated growth but THC failed to replicate this antagonism, which may
have provided some indications as to why only some cannabinoids interacted with radiation.
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Pertinent future studies will include testing JWH-015 and pravadoline as antagonists of S1P
stimulated growth in MCF-7 cells.
Future work should include structure-activity relationship studies to screen analogs of
WIN2 for compounds that are more efficacious at inhibiting MCF-7 cell growth and/or
augmenting the antiproliferative effects of radiation. Structure-activity relationship studies could
be performed even in the absence of a confirmed target of action for WIN2. Identification of
more efficacious analogs of WIN2 as antagonists of S1P stimulated growth, could additionally
screen for compounds that possess less profound cannabimimetic effects compared to the
parent compound WIN2, as these side-effects have impeded clinical development of WIN2 thus
far (Howlett et al. 2002; Pertwee et al. 2010). Decreases in the cannabimimetic effects of these
drugs could also enhance their likelihood of FDA approval, which is the first step to using novel
drugs with radiation augmenting properties like WIN2 to prolong patient survival.
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